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A B S T R A C T
Alzheimer’s disease (AD) is characterized by slowly progressive neuronal death, but its molecular
cascade remains elusive for over 100 years. Since accumulation of autophagic vacuoles (also called
granulo-vacuolar degenerations) represents one of the pathologic hallmarks of degenerating neurons in
AD, a causative connection between autophagy failure and neuronal death should be present. The aim of
this perspective review is at considering such underlying mechanism of AD that age-dependent
oxidative stresses may affect the autophagic-lysosomal system via carbonylation and cleavage of heat-
shock protein 70.1 (Hsp70.1). AD brains exhibit gradual but continual ischemic insults that cause
perturbed Ca2+ homeostasis, calpain activation, amyloid b deposition, and oxidative stresses. Membrane
lipids such as linoleic and arachidonic acids are vulnerable to the cumulative oxidative stresses,
generating a toxic peroxidation product ‘hydroxynonenal’ that can carbonylate Hsp70.1. Recent data
advocate for dual roles of Hsp70.1 as a molecular chaperone for damaged proteins and a guardian of
lysosomal integrity. Accordingly, impairments of lysosomal autophagy and stabilization may be driven
by the calpain-mediated cleavage of carbonylated Hsp70.1, and this causes lysosomal permeabilization
and/or rupture with the resultant release of the cell degradation enzyme, cathepsins (calpain–cathepsin
hypothesis). Here, the author discusses three topics; (1) how age-related decrease in lysosomal and
autophagic activities has a causal connection to programmed neuronal necrosis in sporadic AD, (2) how
genetic factors such as apolipoprotein E and presenilin 1 can facilitate lysosomal destabilization in the
sequential molecular events, and (3) whether a single cascade can simultaneously account for
implications of all players previously reported. In conclusion, Alzheimer neuronal death conceivably
occurs by the similar ‘calpain-hydroxynonenal-Hsp70.1-cathepsin cascade’ with ischemic neuronal
death. Blockade of calpain and/or extra-lysosomal cathepsins as well as scavenging of hydroxynonenal
would become effective AD therapeutic approaches.
 2013 Elsevier Ltd. All rights reserved.
Abbreviations: Ab, amyloid b; AD, Alzheimer’s disease; ALLN, N-acetyl-Leu-Leu- Nle-CHO; apoE, apolipoprotein E; APP, amyloid precursor protein; APPLon, APP containing
the London mutant g-secretase site sequence; APPSwe, APP containing the Swedish mutant b-secretase site sequence; ASM, acid sphingomyelinase; BACE, b-Site APP
cleaving enzyme; BMP, bis(monoacylglycero) phosphate; CA1, cornu Ammonis 1; CerS, ceramide synthase; CHIP, carboxyl terminus of the Hsc70-interacting protein; CNS,
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1.1. Drawback of the amyloid cascade hypothesis
More than one century ago, Dr. Alois Alzheimer (1907)
described two important ﬁndings in the autopsy brain of a
farmer’s wife suffering from severe dementia; one is ‘‘miliar foci
which are caused by deposition of a peculiar substance in the cortex’’
(now recognized as senile plaques), while another is ‘‘very peculiar
changes in the neuroﬁbrils’’ (now recognized as neuroﬁbrillary
tangles). Currently, Alzheimer’s disease (AD) is the most common
(60%) form of dementia in the aged population. It is known to be a
chronic neurodegenerative disorder with an insidious onset and
progressive declines in cognition, memory, attention, and lan-
guage. The risk of AD dramatically increases in individuals beyond
the age of 70. AD begins with abnormal processing of amyloid
precursor protein (APP), which leads to excess accumulation of
amyloid b (Ab) in the brain as senile plaques (Hardy and Selkoe,
2002). Such pathological process occurs gradually, and after a lag
period presumably as long as two decades, neuronal dysfunction
and degeneration become the dominant pathological processes
(Jack et al., 2009). The majority of AD cases are non-genetic,
sporadic forms, whereas merely less than 2.5% of all cases have a
genetic origin. Compared with the healthy brain, the AD brain
exhibits a marked shrinkage of the temporal and frontal lobes, and
is histologically characterized by senile plaques and neuronal loss.
Furthermore, especially cholinergic neurons are ultrastructurally
characterized by neurodegeneration being associated with autop-
hagic vacuoles (also called granulo-vacuolar degenerations),
neuroﬁbrillary tangles and synaptic loss. AD is arguably one of
the most complex diseases of the aged human brain, but a cascade
of molecular events leading to this disease remains grossly
unknown for over a century.
The widely accepted risk factor for developing AD is Ab
deposition due to aging (Bi, 2010). More than 40 years ago, amyloid
peptides were recognized by Glenner (1980a,b) as a major
component of the amorphous plaque-like deposits in the damaged
brains of AD patients. Since then, it became widely accepted that
the amyloid cascade hypothesis best describes the pathogenic
events causing Alzheimer neuronal death and leading ultimately to
irreversible dementia. The amyloid cascade hypothesis (Glenner
and Wong, 1984; Hardy and Selkoe, 2002; Citron, 2004; Herrup,
2010) claims that Ab aggregates trigger a series of downstream
events such as plaque deposition, tau hyperphosphorylation,
inﬂammation, loss of synaptic structure and function, and death of
susceptible neurons. This hypothesis postulates three key events
that divert the brain into its pathophysiology. First, there has to be
a precipitating injury such as vascular event, diabetes, head
trauma, stress/life event, or risk factor genes. Second, a chronic
inﬂammatory process is caused by elevated cytokines and
chemokines that are produced by microglia, astrocytes, and
endothelial cells. Third, a discrete change in the cell biological
state of the brain occurs including widespread synaptic dysfunc-
tion, autophagy defects, selective neuronal loss, and attendant
neurotransmitter deﬁcits (Herrup, 2010).Please cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobIn the human AD brain samples, speciﬁc variants of Ab
peptides, such as Ab1–42, N-terminally truncated Ab2/3–42, and
pyroglutamate-modiﬁed AbN3pE peptides are prevalent. Especial-
ly, the most prominent N-terminal truncated Ab peptide involved
in human amyloid plaques is AbN3pE (Schieb et al., 2011). AbN3pE
starts at residue 3Glu in the form of pyroglutamyl, and is more
hydrophobic than other forms of Ab, thus increasing the
insolubility of Ab (Saido et al., 1995; Kuo et al., 1997). N-
terminally truncated Ab species account for more than 60% of the
Ab peptides in early and later stages of AD amyloid pathology
(Sergeant et al., 2003). In addition, Ab1–42 is also important in the
pathogenesis of AD due to a higher propensity to aggregate (Jarrett
et al., 1993; Jarrett and Lansbury, 1993). The amyloid cascade
starting from depositions of these three peculiar Ab is too complex
web of interactions to view the whole diagram as sequential
events, and this alone can hardly explain the pathogenesis of
Alzheimer neuronal death. So far, Ab deposition has been thought
to be the primary event that triggers the pathological cascade in AD
(Selkoe, 1998). However, the data in support of the amyloid
cascade hypothesis have become questionable for the past decade
(Robakis, 2010), because, (1) vast overproduction of Ab peptides in
the transgenic mice brain failed to cause severe neuronal loss and/
or brain atrophy as seen in the human patients. Furthermore, (2)
substantial amyloid deposits are sometimes (approximately 20–
30%) detected in the brains of senior normal adults who lack any
signs of clinical dementia. In addition, (3) the most serious
drawback of the amyloid hypothesis is its inability to work
therapeutically; i.e. removal of amyloid has contributed to the
reversal of neither memory loss nor cognitive deﬁcits. Nobody can
explain how Ab triggers the pathological cascade, how each
initiating injury causes an inﬂammatory response, and how
neuroinﬂammation alters brain cell physiology.
1.2. From apoptosis to necrosis
In the elderly, vascular risk factors such as arteriosclerosis,
atrial ﬁbrillation, coronary artery disease, hypertension, diabetes
mellitus, smoking, insulin resistance, obesity or metabolic
syndrome, are not only linked to brain aging and stroke but also
signiﬁcantly increase the risk of AD (Mattson, 2009; Stranahan and
Mattson, 2012). Cerebrovascular disease is well-known to hasten
the pathological processes leading to dementia. AD is three times
likely to precipitate in the elderly after a stroke episode or a
transient ischemic attack. Cerebral ischemia may promote
Alzheimer type of changes in the aged brain, while 60–90% of
AD cases exhibit variable cerebrovascular pathology (Kalaria,
2000). Pre-symptomatic vascular lesions such as cerebral amyloid
angiopathy, microvascular degeneration, and periventricular
white matter lesions are evident in almost all cases. Previous
data suggest that almost 30% of AD patients bear evidence of
cerebral infarction at autopsy (Premkumar et al., 1996; Kalaria,
2000). Although cerebral ischemia should have a causal connection
to the development of Alzheimer neuronal death, there is no
concensus about the role of ischemia in neurodegeneration. Both in
vivo and in vitro experimental studies support the notion thater’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
io.2013.02.004
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fragments containing the Ab domain. Furthermore, the soluble Ab
peptides increase in brains of patients who succumb to cerebral
ischemia (Kalaria, 2000).
In the AD brain, neuronal death occurs mainly in the
hippocampus, entorhinal cortex, as well as frontal, parietal and
temporal cortices. Because it occurs over a prolonged time of years,
presumably a relatively small number of neurons are dying at any
time point. Such a spatio-temporal pattern of neuronal death is
considered characteristic of apoptosis and might contrast with
necrosis (Mattson, 2004). Accumulating evidence from the
molecular analyses strengthens involvement of apoptosis by
activations of caspases, p53, Bax, Bad, etc. in the AD brains
(Mattson, 2000; Eckert et al., 2003; McPhie et al., 2003). However,
there are extremely very few, if no, morphologic evidence of
apoptotic bodies in the degenerating neurons in the AD brain
(Figs. 1 and 2). Instead, the degenerating neurons most frequently
show a nucleus with vesicular and/or diffusely-condensed
chromatin distribution (Fig. 1a). Apoptosis is one form of
programmed cell death that involves changes in the cytoplasm,
endoplasmic reticulum (ER), mitochondria and nucleus, whereas
necrosis is another form of programmed cell death that involves
changes especially in lysosomes (Yamashima, 2000). Importantly,
the degenerating AD neurons are characterized by autophagic
vacuoles (Fig. 1, 2c: yellow circles) and/or lysosomal lipidosis
(multilamellar bodies as described later). Recently, it became clear
that neuronal necrosis after ischemia/reperfusion also occurs by
the lysosomal rupture in a very programmed manner (YamashimaFig. 1. Light and electron microscopic photographs of senile plaques and degeneratin
neuroﬁbrillary tangles are shown by curved white arrows. The senile plaques are ﬁbrillar 
neuroﬁbrillary tangles comprise of microtubule-associated protein tau that was abnorm
degenerating neurons, showing bright (white arrows) and dark (black arrows) neclei, are 
are characterized by microvacuoles or granulo-vacuolar degenerations in the perikarya (
distribution without forming apoptotic bodies. The neuritic crown of senile plaques appe
neuron in the corona of the senile plaque was observed by electron microscopy (b). Bar =
(vacuoles) in the dystrophic neurites (white asterisks), are seen adjacent to an amyloid d
retrograde transport (Fig. 5a) are impeded, a massive accumulation of these vesicles occu
constitute more than 95% of the organelles in the dystrophic neurites, implying a cargo-s
in the vicinity of the amyloid core contains abundant amyloid deposits (white arrow), lip
latter is consistent with a granulo-vacuolar degeneration on light microscopy. Bar = 2 m
relatively healthy AD neuron. Please, note that small aggregates of amyloid (arrows) are 
courtesy of Prof. Ralph A. Nixon, Nathan Kline Institute, New York).
Please cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobet al., 1996, 1998, 2003; Syntichaki et al., 2002; Yamashima, 2000,
2004, 2012; Artal-Sanz et al., 2006; Yamashima and Oikawa, 2009;
Zhu et al., 2012). Taken together, one can assume that apoptosis is
not the only form of neuronal death in the AD brain, instead,
necrosis might be implicated for its occurrence.
Compared to the age-matched control brains, the Alzheimer
brain being analyzed by terminal deoxynucleotidyl transferase dUTP
and labeling (TUNEL) method, showed a 3- to 6-fold increase of DNA
fragmentation (Jellinger and Stadelmann, 2001). Obviously, such
DNA fragmentation is too frequent to account for the continuous but
gradual neuronal death in this slowly progressive disease. This is
presumably because apoptosis is occurring mainly in the reactive
microglia and oligodendroglia. Apoptotic neuronal death was
extremely rare in the hippocampus; only one out of 2600–5650
hippocampal neurons displayed strong cytoplasmic labeling for
activated caspase 3, and typical apoptotic morphology; i.e. reduction
in cell size, chromatin condensation, and formation of apoptotic
bodies (Jellinger and Stadelmann, 2001). Such extremely low
incidence appears realistic in view of the protracted course of AD,
compared to the very short duration (presumably less than one day)
required for the completion of apoptosis. Intriguingly, the majority
of TUNEL-positive neurons in the familiar AD bearing presenilin 1
mutation, showed ultrastructural features of not apoptosis but
necrosis (Velez-Pardo et al., 2001). Neurons of the sporadic AD were
characterized by endosomal/lysosomal abnormalities such as
autophagosomes and/or autolysosomes containing multilamellar
bodies (Nixon et al., 2005). Taken together, increased DNA
fragmentation in the susceptible neurons does not necessarilyg neurons in AD. (a) The senile plaques are indicated by the asterisks, while the
aggregates of Ab being interspersed among clusters of dystrophic neurites, while the
ally phosphorylated and aggregated into paired helical ﬁlaments. Two types of the
seen in the corona of the senile plaques (asterisks). The bright degenerating neurons
yellow circles). Neuronal nuclei generally exhibit vesicular or condensed chromatin
ars to incorporate these degenerating neurons and their neurites. One degenerating
 50 mm, Bielschowsky’s silver stain. (b) Accumulation of autophagic dense vesicles
eposit (black asterisk). Since maturation (Fig. 7a) of autophagolysosomes and their
r within dystrophic and degenerating neurites. Autophagic vacuoles and lysosomes
peciﬁc defect in the axonal transport (Fig. 5). The degenerating neuron (black circle)
ofuscin granules (black arrow), and a multivesicular body (MVB; yellow circle). The
m. (c) Ultrastructural appearance of MVBs (yellow circle) in the perikarya of the
usually adhering to the MVBs. Compare this with Figs. 2c and 6c. Bar = 2 mm (by the
er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
io.2013.02.004
Fig. 2. Light and electron microscopic photographs of normal and AD neurons. (a) In the normal neuron of an age-matched control subject, the nucleus shows a vesicular
chromatin condensation with a prominent nucleolus. The perikarya contains numerous organelles such as mitochondria, lysosomes and ER. EM: Bar = 2 mm, LM:
Bielschowsky’s silver staining. (b) The perikarya of the degenerating AD neuron contains neuroﬁbrillary tangles (arrows) while the neurite is packed with numerous
lipofuscin granules (black asterisk). EM: Bar = 2 mm, LM: Bielschowsky’s silver staining. (c) The perikarya of the degenerating AD neuron shows 4G8-positive amyloid
deposition and accumulation of autophagic vacuoles (also called granulo-vacuolar degenerations); both being adjacent to each other on light microscopy (insert; arrow).
Here, the autophagic vacuoles are ultrastructurally revealed as MVBs (yellow circles). The irregular dense bodies (white asterisk) adjacent to the autophagic vacuoles can be
identiﬁed as Ab by comparing spatial relations on light and electron microscopy. Since MVBs cannot completely engulf Ab peptide within their lumen, bundles of Ab ﬁbrils
conceivably penetrate the vesicular membrane and transfer to the cytoplasm, as shown in Fig. 6c. Accordingly, the intracellular Ab (white asterisk) is often localized in the
close vicinity of MLBs. LM: Ab immunostaining using 4G8 antibody (Covance, Princeton, New Jersey, USA), EM: Bar = 2 mm (by the courtesy of Prof. Ralph A. Nixon, Nathan
Kline Institute, New York).
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and accelerated DNA damage. Cells with these DNA disorders may
show increased vulnerability toward hypoxia, oxidative stress,
neurotoxins, etc. Accordingly, the intracellular cascade leading to
neuronal death still awaits further elucidation in AD. Alternative
mechanism of neuronal death should be considered so as to explain
chronic and gradual progression of this disease.
1.3. Insights from ischemic to degenerative neuronal death
Axons, dendrites and spines are exposed to many different
environmental conditions and signaling molecules. High content of
APP, presenilins, and tau, as well as high metabolic and oxidative
loads, may render synapses vulnerable. Synapses may be
particularly susceptible to the adverse effects of aggregating
forms of Ab, because the latter may disturb neuronal functions by
inducing oxidative stresses and disrupting cellular Ca2+ homeo-
stasis. Oxidative stresses generate powerful oxidant, 4-hydroxy-2-
nonenal (HNE; Fig. 4a) via peroxidation of membrane lipids such as
linoleic and arachidonic acids. HNE is a strong electrophile and has
the ability to readily adduct and damage proteins. Immunohisto-
chemical analysis of the postmortem Alzheimer brains revealed
increased protein modiﬁcation by HNE (Sayre et al., 1997). When
Ab aggregation occurs close to the cell membrane, membrane-
associated oxidative stress results in lipid peroxidation and the
consequent generation of HNE may modify membrane transpor-
ters, receptors and ion channels (Mattson, 2009). Furthermore,
oxidative modiﬁcations of tau by HNE can promote ﬁbrillary
aggregation and may thereby induce the formation of neuroﬁbril-
lary tangles (Mattson, 2004). Inheritance of the apolipoprotein Ee4
allele (apoE4) is accepted to increase the risk for AD at an earlier
age, because apoE4 lacking cysteine residues in its key sites cannotPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobdetoxify HNE (Pedersen et al., 2000; Tokuda et al., 2000). HNE is
known to mediate toxic effects of Ab to cultured hippocampal and
cortical neurons. Identifying the mechanism of HNE-induced
neuronal death pathways may be critical for understanding the
pathogenesis of AD.
Recent research has underscored the roles of lysosomal
pathways in AD, because deﬁciency or mutation in the presenilin
1 gene impairs maturation of the lysosomal proton pump (Lee
et al., 2010). Neurons that degenerate in AD exhibit perturbed
cellular Ca2+ homeostasis. As a mechanism of ischemic neuronal
death, in 1998 Yamashima et al. formulated the ‘calpain–cathepsin
hypothesis’, according to which Ca2+-activated cysteine protease
‘m-calpain’ compromises integrity of lysosomal membranes
and causes leakage of lysosomal acidic hydrolase ‘cathepsins’
into the cytoplasm (Yamashima et al., 1998). Calpain activation
and/or HNE-induced carbonylation of heat-shock protein 70.1
(Hsp70.1; simply Hsp70, also called Hsp72 or HSPA1 indicating a
major protein of the human Hsp70 family) have been conﬁrmed
not only in the ischemic monkey brain (Sahara and Yamashima,
2010) but also in the Alzheimer brains (Saito et al., 1993;
Taniguchi et al., 2001; Sultana et al., 2010). Recent data advocate
for a deﬁnite role for Hsp70 not only as a chaperone protein for
damaged proteins but also as a guardian of lysosomal integrity
(Kirkegaard et al., 2010). Accordingly, failure of lysosomal
autophagy and proteolysis is driven by calpain-mediated
cleavage of carbonylated Hsp70.1, that is promoted by chronic
mild hypoxia and Ab deposition due to aging, environmental risk
factors and resultant oxidative stresses, and apoE4’s incapability
of detoxifying HNE. Deﬁciency of presenilin 1 disturbs acidiﬁca-
tion necessary for the recycling of proteins and lipids which may
cause an enormous storage of undigested materials within
autophagic vaculoes.er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
io.2013.02.004
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deposition (Fig. 1a) has been considered mediators of neurotoxici-
ty in AD, recent ﬁndings have raised doubts about the amyloid
cascade hypothesis (Bi, 2010). Ab deposition, oxidative stresses,
inﬂammatory reactions, and AD-related gene mutations are
accepted to be possible causative factors. However, no single
cascade reported previously can simultaneously account for
implications of all of these. This review proposes such a concept
that long-standing, mild cerebral ischemia initiates ‘calpain-
mediated cleavage of carbonylated Hsp70.1’, and the resultant
lipidosis, membrane destabilization, and/or rupture of lysosomes
are the main causes of programmed neuronal necrosis in AD.
Because most cases of AD are sporadic and late-onset, the most
important risk factor should be age-related lysosomal destabiliza-
tions. Primary lysosomal dysfunction in congenital neurodegener-
ative diseases is well known, however, the possibility was only
recently recognized that neurodegeneration secondary to age-
related dysfunctions in lysosomal resident and/or interacting
factors may also lead to acquired neurodegenerative diseases
(Yamashima, 2012). Here, the author discusses how each of the
common Alzheimer’s susceptibility genes and other well-known
risk factors promoting AD contribute to lysosomal dysfunction,
destabilization, and rupture.Fig. 3. The role of age-dependent capillary changes in AD neurodegeneration. AD patients
barrier. Inﬂammatory reactions, ROS, resultant Ab depositions, and apoE4 inappropriate
patients with AD and Parkinson’s disease with dementia as well, age-related, degenerativ
non-ﬁbrillary form or delicate ﬁbrils in the capillary basement membrane (cited from P
basement membrane deposits and/or ﬁbrosis in three different conditions. C, non-dem
*P < 0.05 (cited from Prog Neurobiol 64, 575–611, 2001). (c) Basement membrane path
nutrients from blood into the brain parenchyma. Reduction of the cerebral microcircu
neurons, that lead to cognitive deﬁcits. Then, chronic hypertension may accomplish its de
Prog Neurobiol 64, 575–611, 2001). (d) The calpain activation in the AD brains occurs app
controls. Arrow indicates 76 kDa bands indicating activated m-calpain (cited from FEB
Please cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurob2. Possibility of Hsp70.1 cleavage in Alzheimer’s disease
2.1. Calpain activation in the Alzheimer brain
Intriguingly, Dr. Alois Alzheimer (1907) described that ‘‘besides
storage of peculiar material in the cortex, one sees endothelial
proliferation and also occasionally neovascularization’’. Here, we
should note that ischemic pathology was already evident in his
ﬁrst AD case. Alzheimer described microvascular changes, in terms
of ‘‘endothelial proliferation’’ and ‘‘neovascularization’’. Many years
later, Fischer et al. (1990) also conﬁrmed a striking and statistically
signiﬁcant reduction in the vascular net density speciﬁcally in the
basal forebrain region and the hippocampus of AD brains. In the
last two decades, the contribution of vascular factors to the
etiology of AD has become a rapidly extending research ﬁeld. Both
Ab- and oxidative stress-induced inﬂammatory damages to small
blood vessels and the resultant reduction of the regional cerebral
blood ﬂow (rCBF), were thought to be critical for the occurrence of
Alzheimer neuronal death (Fig. 3a–c) (Marchesi, 2011).
The majority (70–90%) of AD patients show cerebral amyloid
angiopathy which narrows the vessels and causes cerebral
ischemia (Farkas and Luiten, 2001; Cullen et al., 2006; Hardy
and Cullen, 2006; Smith and Greenberg, 2009). There is a general often show amyloid pathology in their small vessels, which impairs the blood-brain
ly collaborate to damage capillaries as the ﬁrst step of cerebral ischemia. (a) In the
e capillary changes occur at the basement membrane. Ab may accumulate either in a
rog Neurobiol 64, 575–611, 2001). (b) The percentage of cerebral capillaries with
ented control; AD, Alzheimer’s disease; PDd, Parkinson’s disease with dementia.
ology (Fig. 3a) will physically hinder passive transport of glucose, electrolytes and
lation may enhance synaptic loss and neurodegeneration especially of cholinergic
trimental effects on cerebral vessels via inducing cerebral hypoperfusion (cited from
roximately seven-fold more intense, compared to the age-matched, non-demented
S Lett 489, 46–50, 2001).
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Fig. 4. 4-hydroxy-2-nonenal (HNE)-mediated carbonylation and calpain-mediated cleavage of Hsp70.1 in the monkey hippocampus. (a) Chemical structure of HNE being
generated from v = 6 polyunsaturated fatty acids such as linoleic and arachidonic acids. In response to HNE being generated by the oxidative stress during the reperfusion,
carbonylation occurs at the key site, Arg469 of Hsp70.1 in the CA1 tissue. A decrease of the molecular weight from 157.20 to 113.12 indicates an insult by the oxidative stress
(cited from Free Radic Biol Med 46, 1472–1477, 2009). (b) Two-dimensional carbonyl immunoblots of the human brain samples after immunoprecipitation with anti-Hsp70
antibody, shows upregulation of carbonylated Hsp70 in the patient with mild cognitive impairment (MCI), compared to the control subject (CTR) (cited from Antioxid Redox
Signal 12, 327–336, 2010). (c) Hsp70.1 (green) and activated m-calpain (red) were shown to be colocalized by immunohistochemistry in the monkey CA1 neurons, especially
on days 3 (d3) and 5 (d5) after transient ischemia. Scale bar = 10 mm. (d) In vitro cleavage of Hsp70.1 being involved in the normal CA1 tissue after incubation with 0.2, 0.5, and
1.0 U of activated m-calpain. (e) Dose-dependent blockade upon calpain-mediated cleavage of carbonylated-Hsp70.1 by HNE, using a speciﬁc calpain inhibitor N-acetyl-Leu-
Leu-Nle-CHO (ALLN). Please, note that Hsp70.1 cleavage by calpain occurs more drastically following HNE-mediated carbonylation (Fig. 5d and e: red circles).
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compared to the age-matched controls) cerebral perfusion in AD
patients, and reduction of the rCBF was proportional to the degree
of cognitive decline (Farkas and Luiten, 2001). Nerve terminals
from the cholinergic neurons of the basal nucleus of Meynert
interact with astrocytic end feet of the blood-brain barrier via
muscarinic acetylcholine receptors (Vaucher and Hamel, 1995;
Farkas and Luiten, 2001). Accordingly, a marked reduction
predominantly of cholinergic neurons occurs in the basal forebrain
(septum and nucleus basalis of Meynert) in advanced stages of AD
that was associated with long-standing cerebral hypoperfusion
(Wilcock et al., 1982; Whitehouse et al., 1983). Whereas the
substantial contribution of the cholinergic pathways to cognitive
functions is widely accepted, recently the striking coincidence of
cholinergic neurodegeneration in the nucleus basalis and the
reduced rCBF has also gained more attention in AD patients
(Fig. 3c) (Farkas and Luiten, 2001).
The Alzheimer brains bear vascular pathology being capable of
inducing cerebral infarcts, microinfarction, white matter changes
related to small vessel disease, and even hemorrhages (Kalaria,
1996, 2000; Kalaria and Ballard, 1999). Since patients with
cerebrovascular disease or vascular dementia often bear AD
pathology at autopsy even though absence of pre-existing AD
symptoms, there should be a causal connection between cerebral
ischemia and AD (Kalaria, 2000). It is important to point out that inPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobthe early stage of AD, damaged vessels are at the capillary,
arteriole, and venule level, not at the large muscular artery level
(Fig. 3a and b). Damaged microvasculature creates ischemic
conditions that might be initially conﬁned to small areas of brain
tissue, possibly affecting only a small number of neurons
(Marchesi, 2011). Although stroke and severe cardiovascular
diseases had been normally considered exclusion criteria for the
clinical diagnosis of AD, the contribution of cerebral ischemia to AD
neurodegeneration is nowadays apparent (Fig. 3c).
Calpain (EC 3.4.22.17) is an intracellular, non-lysosomal, Ca2+-
dependent, papain-like protease. For the half-maximal activity, m-
calpain requires micromolar (3–50 mM) levels of Ca2+, whereas m-
calpain requires nearly millimolar (400–800 mM) levels of Ca2+. In
the hippocampus, m-calpain is localized at the pyramidal and
granular neurons, whereas m-calpain is localized at the inter-
neurons (Rami, 2003). Calpain participates in various Ca2+-
mediated signaling pathways by modulating activities and/or
functions of other proteins. It is also responsible for the turnover of
substrates being related to the cell mobility, and cell cycle
progression (Suzuki et al., 2004). Physiologically, calpain is present
in the cytosol as inactive precursors, but extreme conditions often
result in overactivation of calpain, and activated calpain transfers
to the membrane fractions. Not only cerebral ischemia (Yama-
shima et al., 1996, 1998, 2003; Yamashima, 2000, 2004) but also
wild-type APP (Kuwako et al., 2002) and Ab (Reifert et al., 2011)er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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note that the AD brains show as high as 7-fold m-calpain activation,
compared to the age-matched control brains (Fig. 3d) (Taniguchi
et al., 2001).
In AD, m-calpain was suggested to be involved in the processing
of not only APP (Siman et al., 1990) but also tau proteins (Mercken
et al., 1995; Yang and Ksiezak-Reding, 1995). Activated calpain was
found to co-localize with neuroﬁbrillary tangles, senile plaques,
and dystrophic neurites (Saito et al., 1993). An inﬂammatory
response accompanies tissue damage in many brain diseases, and
AD is unique in the intimate association found between chronic
inﬂammation and disease (Herrup, 2010). Epidemiological evi-
dence shows that long-term use of high doses of non-steroidal
anti-inﬂammatory drugs (NSAID) lowers the lifetime risk of AD by
30–60% (McGeer et al., 1996; Stewart et al., 1997; Vlad et al., 2008;
Herrup, 2010). This is presumably because NSAID such as
indomethacin and NS-398 [N-[2-(cyclohexyloxy)-4-nitrophenyl]-
methanesulfonamide]) can inhibit not only cyclooxegenase
enzymes but also calpain activity (Raveendran et al., 2008; Silver
et al., 2010). Although calpain has been suggested to be one of the
principal effectors of the pathogenesis of AD (Nixon et al., 1994), its
exact role in the Alzheimer neurodegeneration still remains
unclariﬁed.
2.2. Increment of a key substance, ‘hydroxynonenal’
The brain is particularly susceptible to oxidative stresses
because of its high content of peroxidizable polyunsaturated fatty
acids, high oxygen consumption, high levels of free radical-
inducing iron/ascorbate, and relatively low levels of anti-oxidant
defense systems (Floyd, 1999; Poon et al., 2004a,b; Halliwell,
2006). Reactive oxygen species (ROS)-mediated oxidative stresses
play a crucial role in the age-related decline of brain function as a
result of the oxidation of nucleic acids, lipids, and proteins.
Actually, proteins have many amino acid residues that are more
susceptible to the oxidative stresses than deoxyguanosine in DNA.
The pathophysiological meaning of variously oxidized protein
molecules has been discussed not only in AD but also in aging,
atherosclerosis, cataracts, glaucoma, cerebral ischemia, etc.
Furthermore, ROS have the potential to chemically modify
membrane lipids, as shown by elevation of lipid oxidation products
in the AD brains (Singh et al., 2010). Lipid peroxidation leads to the
formation of a number of aldehyde by-products, including HNE,
malondialdehyde (MDA), and acrolein (Esterbauer et al., 1991;
Schneider et al., 2001). The most abundant aldehydes are HNE and
MDA, while acrolein is the most reactive. Marked increase of HNE
was reported in the hippocampus as well as in the superior and
middle temporal gyri of patients with mild cognitive impairment
(MCI) or early AD, compared to age-matched healthy individuals
(Williams et al., 2006). Elevations in the free HNE concentration
have been detected in the cerebrospinal ﬂuid of AD patients (Lovell
et al., 1997). This suggests that HNE is diffusible in the brain and
can therefore modify proteins other than those located at the site
where HNE was generated (Pedersen et al., 2000). HNE application
can in vitro mimic AD pathology, including modiﬁcation of tau
(Takeda et al., 2000; Liu et al., 2005) and Ab (Murray et al., 2007),
inhibition of the glucose transporter (Reagan et al., 2000), and
disruption of microtubules (Gadoni et al., 1993).
HNE is a major polar lipophilic secondary peroxidation product
which can be generated from v-6 polyunsaturated fatty acids such
as linoleic and arachidonic acids when cooked at frying tempera-
ture (Esterbauer et al., 1991; Esterbauer, 1993). Abundant linoleic
acid is involved in vegetable oils; for example, about 60% in corn
oils and about 54% in soybean oils (Sonntag, 1979). Vegetable oils
are worldwide used for frying, because of the convenience and low
cost, however, these oils are especially susceptible to oxidation atPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobhigh temperature (Kilgore, 1969; Kilgore and Bailey, 1970; Kilgore
and Windham, 1973; Chang et al., 1978; Gere, 1982). Continuous
or intermittent exposure of the vegetable oils to the frying
temperature (185–220 8C) steadily accerates the formation of HNE
(Seppanen and Csallany, 2006), because its formation is highly
affected by the concentration of linoleic acid involved in the oils
(Han and Csallany, 2008). It is widely accepted that HNE
contributes to the development of neurodegeneration (Mattson,
2009), but the underlying mechanism has been unknown until
recently. In studies on the role of lipid peroxidation in the
pathogenesis of ischemic neuronal death, it was shown that
Hsp70.1 is carbonylated by HNE (Oikawa et al., 2009; Yamashima
and Oikawa, 2009; Sahara and Yamashima, 2010). This ﬁnding is of
particular interest in relation to Alzheimer neuronal death as apoE
genotype modiﬁes its risk by detoxifying HNE (Pederson et al.,
2000). It is well known that non-demented individuals carrying an
apoE4 allele, a common Alzheimer’s susceptibility gene (Corder
et al., 1993; Strittmatter et al., 1993a,b), have cerebral glucose
hypometabolism as compared to apoE4 non-carriers, and show
progressive cognitive deterioration, correlating with the reduction
of glucose metabolism (Small et al., 1995; Reiman et al., 1996;
Small et al., 2000; Reiman et al., 2001, 2004).
Fluorodeoxyglucose-positron emission tomography studies
have shown that AD patients have abnormally low cerebral
metabolic rates for glucose in the posterior cingulate, parietal,
temporal, and prefrontal cortices. Furthermore, carriers of the
apoE4 allele have similar brain abnormalities already in young
adulthood, several decades before the possible onset of dementia
(Reiman et al., 2004). Furthermore, carriers of the apoE4 allele are
associated with up to half cases of late-onset AD (Corder et al.,
1993; Saunders et al., 1993; Strittmatter et al., 1993a,b). The E4
isoform of apoE is known to be associated with increased Ab
aggregation, less protection against Ab-induced oxidative neuro-
toxicity, less efﬁcient repair of neurons and synapses, less
protection against the hyperphosphorylation of the microtu-
bule-associated protein tau, and the formation of neuroﬁbrillary
tangles (Mahley, 1988; Strittmatter et al., 1993a,b, 1994a,b;
Wisniewski et al., 1994; Miyata and Smith, 1996).
The highest expression of apoE is in the liver, followed by the
brain; neurons and astrocytes are the major cell types that express
apoE in the brain (Pitas et al., 1987; Xu et al., 1999; Grehan et al.,
2001; Xu et al., 2006). ApoE plays a key role in lipid transport
throughout the body, and in the brain it is involved in the
maintenance and repair of neurons (Mahley, 1988; Weisgraber
and Mahley, 1996). Cholesterol being released from apoE-containing
lipoprotein particles, is used to support synaptogenesis and synaptic
connections (Pfrieger, 2003). While many putative susceptibility
genes for AD have been reported to date, polymorphism in the apoE
gene is the only conﬁrmed genetic risk factor for sporadic AD; with
the e4 allele being an AD risk factor and the e2 allele being protective
(Corder et al., 1993; Strittmatter et al., 1993a,b). However, the
mechanism by which apoE polymorphism inﬂuences occurrence
and progression of late-onset AD has yet to be proven. The three
common isoforms of apoE comprise of apoE2 (cys112, cys158),
apoE3 (cys112, arg158), and apoE4 (arg112, arg158). The differences
by only one or two amino acids at residue 112 or 158 greatly alter
apoE structure and function (Mahley et al., 2006).
The risk for AD increases 23-fold in individuals with one e4
allele while about 12-fold in those with two e4 alleles (Roses,
1996). The e2 allele of apoE is associated with a lower risk for AD
(Corder et al., 1994; Farrer et al., 1997), while the apoE e4 allele is
also associated with an earlier onset of AD (Gomez-Isla et al., 1996;
Roses, 1996). This can be partly explained by the scant binding of
apoE4 with Ab which accelerates its deposition (Strittmatter et al.,
1993b; Wisniewski et al., 1994), because the efﬁciency of
complex formation follows the order of apoE2 > apoE3  apoE4er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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Ab clearance, that lead to promoting cerebrovascular pathology
and increasing oxidative stresses (Mattson, 2004). Accumulation of
aggregated Ab1–42 in late endosomes or secondary lysosomes may
directly damage lysosomal membrane integrity (Yang et al., 1998).
Furthermore, both the endosomal trafﬁcking and colocalization
with cathepsin D in cultured human brain neurons, occurs more
frequently in apoE4 than apoE3 (DeKroon and Armati, 2001). Taken
together, it is likely that the insertion of apoE4 into the lysosomal
membrane may also facilitate neurotoxicity of Ab peptide by
destabilizing lysosomal membrane (Yuan et al., 2003).
Furthermore, apoE4 is more unstable than apoE3 and exists
uniquely in ‘molten globules’ at low pH. Low pH in lysosomes
favors the molten globular structure in apoE4 proteins which are
susceptible to forming reactive intermediates. One of the distinc-
tive properties of reactive intermediates is avid binding to
phospholipid and membranes and the ability to alter and disrupt
membrane structure (Dobson, 2001; Morrow et al., 2002).
Although apoE4 alone cannot cause lysosomal leakage, Ab,
working in concert, facilitates release of lysosomal enzymes into
the cytosol. This occurred more signiﬁcantly using the arctic
mutant Ab which is prone to aggregation and ﬁbril formation than
GM6 mutant Ab which is highly resistant to multimerization or
aggregation (Ji et al., 2006). The greater propensity of apoE4 than
apoE3 or apoE2 to form a molten globule has potential implications
in neurodegeneration. In addition, the capacity of human apoE
binding with HNE, thus, eliminating free HNE, is in the order of
apoE2 > apoE3  apoE4, and this was in agreement with the
preventive activity of apoE against cell death caused by HNE
(Pedersen et al., 2000). Accordingly, the possession of apoE 4 with
the weakest HNE elimination ability leads to accumulation of HNE
in neurons.
2.3. Calpain cleavage of carbonylated Hsp70.1
Although the earliest detectable pathological change in the AD
brain is at present thought to be Ab accumulation, it is likely that
Ab accumulation is necessary but not sufﬁcient to produce the
clinical dementia. It is well known that some individuals show all
of the diagnostic neuropathological evidence of AD at autopsy
without expressing dementia during their life. It is also true that
other individuals are relatively resistant to Ab depositions because
of protective genetic factors, environmental inﬂuences, exercise,
and/or nutritional interventions (Stranahan and Mattson, 2012).
Presumably, cognitive decline would occur only in the setting of
Ab depositions plus certain event (for example, synaptic loss)
prone to neurodegeneration (Sperling et al., 2009). Then, what is
the more essential and indispensable causative factor of neuro-
degeneration in AD?
Enhanced proteolysis may explain neurodegeneration in
relation to ischemia/reperfusion or age-related cerebral ischemia.
Widespread activation of m-calpain is well known to occur in the
AD brains, showing a 3–7-fold increase (Fig. 3d) (Saito et al., 1993;
Taniguchi et al., 2001). Given the large number and wide range of
physiological m-calpain substrates, however, it is difﬁcult to detect
the in vivo substrate in the pathological conditions (Bevers and
Neumar, 2008). Accordingly, much had remained unknown until
recently about the precise mechanism of calpain-mediated
neuronal injury and the speciﬁc calpain substrate in vivo that
plays a central role in the neuronal death following ischemia/
reperfusion. Intriguingly, using the monkey brains, Oikawa et al.
(2009) found that carbonyl modiﬁcation of Hsp70.1 is remarkably
(more than 10 fold) increased in the hippocampal CA1 tissues after
ischemia/reperfusion, and the carbonylation site is Arg469 (i.e. key
site) of Hsp70.1 (Fig. 4a). In addition, from the in vitro
experimental paradigm, Sahara and Yamashima (2010) suggestedPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobthat the in vivo calapain substrate in the postischemic CA1 neurons
should be ‘carbonylated Hsp70.10. They found that carbonylated
Hsp70.1 in the CA1 tissue becomes much more susceptible to the
calpain cleavage after artiﬁcial oxidative injuries by HNE (Fig. 4c–
e) or hydrogen peroxide.
Wei et al. (1995) ﬁrst reported a role for Hsp70 as an essential
factor for cancer cell survival in its depletion study (Kirkegaard and
Ja¨a¨ttela¨, 2009). The cancer cell death induced by the depletion of
Hsp70 was characterized by the release of cathepsins into the
cytosol, and cathepsin inhibition provided a signiﬁcant cytopro-
tection (Nylandsted et al., 2000; Nylandsted et al., 2004).
Furthermore, exogenous Hsp70 effectively inhibited lysosomal
destabilization induced by various stresses (Nylandsted et al.,
2004; Gyrd-Hansen et al., 2006; Bivik et al., 2007). It is suggested
from these data that the potent cytoprotective effect of Hsp70 is
partially due to stabilization of lysosomal membranes. Both
calpain activation and HNE-induced carbonylation of Hsp70.1
were identiﬁed not only in the ischemic monkey brain but also in
the brain of mild cognitive impairment (MCI) (Fig. 4b) and
Alzheimer patients (Sultana et al., 2010). Accordingly, the concept
of ‘calpain-mediated cleavage of carbonylated Hsp70.1’ (Sahara
and Yamashima, 2010), presumably contributes to establishing a
relationship between ischemic and degenerative neuronal death
(Yamashima, 2012). Here, the author would like to forward such an
insight that Alzheimer neuronal death may occur by the same
calpain–cathepsin cascade with ischemic neuronal death.
Interestingly, Hsp70.1 dysfunction can also explain the
mechanism of neuroﬁbrillary tangle formation (Fig. 5b). Tau is a
microtubule-associated protein predominantly expressed in
axons, and plays an important role in the maintenance and
stabilization of microtubules. While normal tau promotes assem-
bly and stabilizes microtubules, the non-ﬁbrillized, abnormally
hyperphosphorylated tau sequesters normal tau and disrupts
microtubules. Since mutations in the tau gene cause hereditary
tauopathies including Pick’s disease, corticobasal degeneration,
and progressive supranuclear palsy, tau dysfunction is sufﬁcient to
cause neuronal degeneration (Feany and Dickson, 1996). In AD, tau
dissociates from microtubules and self-associates to form both
ﬁbrillar and preﬁbrillar oligomeric aggregates (Iqbal et al., 2009;
Patterson et al., 2011a). Aggregation and accumulation of tau form
neuroﬁbrillary tangles which inhibit kinesin-dependent fast
axonal transport. This becomes critical for neuronal function,
causing cognitive decline and neuronal degeneration in AD.
However, Hsp70, as a molecular chaperone, prevents protein
misfolding and aggregation. Previous data (Dou et al., 2003;
Petrucelli et al., 2004) suggest that Hsp70 attenuates tau toxicity
by maintaining tau in a soluble, non-aggregated state and by
facilitating degradation of aggregated tau species. Hsp70 interacts
directly with ubiquitin ligase, carboxyl terminus of the Hsc70-
interacting protein (CHIP) that has bound insoluble and hyperpho-
sphorylated tau to regulate its ubiquitination, degradation and
aggregation (Petrucelli et al., 2004; Dickey et al., 2006). Recently,
Patterson et al. (2011b) demonstrated that Hsp70 directly inhibits
tau aggregation by a mechanism involving preferential associa-
tions with soluble, monomeric and preﬁbrillar oligomeric tau
species, and that Hsp70 prevents the toxic effect of preformed tau
aggregates on anterograde fast axonal transport (Fig. 5b). Accord-
ingly, Hsp70.1 disorder can cause not only lysosomal stabilization
but also tau aggregation.
3. Hsp70-related molecules indispensable for the lysosomal
stabilization
Lysosomes degrade a variety of macromolecules such as
proteins, glycoconjugates, lipids, and nucleic acids to their building
blocks (Cuervo and Dice, 1998). They provide cells with the abilityer’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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Fig. 5. Trafﬁcking of autophagic vacuoles (AVs) along the microtuble, and its impairment by Hsp70 dysfunction. (a) Endocytosis and autophagy are highly active at synaptic
terminals. For the efﬁcient clearance of endosomes (Endo) and pre-autophagosomal membranes (Ap) being formed in synapses, nascent AVs mature to autophagolysosomes
during their retrograde transport, by fusing with anterogradely transported lysosomes (Lyso). The kinesin carrying cargo (Fig. 5b) and the microtuble function like a train and
railway, respectively, for such an axonal transport (cited from J Cell Sci 120, 4081–4091, 2007). (b) Model of the effects of Hsp70 dysfunction on tau aggregation. Displacement
of tau from the microtubule allows for its self-association and deposition. However, molecular chaperone Hsp70 binds soluble, monomeric tau that dissociates from the
microtubule, thus preventing both tau aggregates and their inhibition on kinesin-dependent fast axonal transport. Accordingly, Hsp70 dysfunction ( ) which was caused by
its carbonylation and cleavage (Fig. 4), leads initially to tau aggregation, and eventually to the impaired axonal transport. Simultaneously, Hsp70 dysfunction may cause
neurodeneration, because impaired axonal transport disturbs maturation of autophagosomes and this leads to the destabilization of late endosomes/lysosomes (cited from
Biochemistry 50, 10300–10310, 2011).
T. Yamashima / Progress in Neurobiology xxx (2013) xxx–xxx 9
G Model
PRONEU-1261; No. of Pages 23to recycle long-lived proteins and damaged organelles by
autophagy. Autophagy is of special relevance also for the
membrane trafﬁcking and degradation, and another role of
autophagy is that it is a source of bis(monoacylglycerol)phosphate
(BMP) (also called lysobisphosphatidic acid). BMP is not present at
the limiting (perimeter) lysosomal membrane, but is required for
sphingolipid degradation at inner membranes of the acidic
lysosomal compartments (Kolter and Sandhoff, 2010). Biosynthet-
ically, BMP is formed during the degradation of phosphatidylgly-
cerol and cardiolipin, presumably at the surface of intra-lysosomal
vesicles (Amidon et al., 1996; Brotherus and Renkonen, 1977;
Schulze et al., 2009). Phosphatidylglycerol is generated in the ER,
while cardiolipin reaches the lysosome as a component of
mitochondria by macroautophagy.
Since the discovery in the pig and rabbit lung by Body and Gray
(1967), BMP has retained attention due to its original biochemical
characteristics and its massive accumulation in lysosomal
disorders. BMP is a minor lipid that accounts for only 1–2% of
the total phospholipids of the mammalian tissues and cells.
However, it is highly enriched in the internal membranes of late
endosomes, accounting for about 15% of the phospholipids of this
organelle and up to 70% of speciﬁc domains of internal membranes
(Kobayashi et al., 1998, 2002). BMP plays an important role
especially in the control of cellular cholesterol distribution, and
also in the late endosomal/lysosomal degradative pathway. It
exhibits an unusual sn1:sn10 stereoconﬁguration, based on the
position of the phosphate moiety on the carbon 1 and 10 of the
glycerol backbone (Hullin-Matsuda et al., 2009). One fatty acid is
attached to each of the glycerol moieties, for example, docosahex-
aenoic acid (DHA) and DHA (22:6n-3), stearic acid and arachidonic
acid, or oleic acid and oleic acid. One characterisic of BMP is aPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobselective incorporation of DHA, which may confer speciﬁc
biophysical and functional properties. The mechanisms underlying
both the high proportion of DHA in BMP and the formation of 22:6/
22:6-BMP molecular species are still unknown (Hullin-Matsuda
et al., 2009). However, it is likely that BMP molecules containing
DHA will favor increased membrane ﬂuidity or membrane fusion
with Hsp70.1 and/or lysosomal internal membranes owing to its
ﬂexibility (Fig. 6a). However, 22:6/22:6-BMP becomes a privileged
target for lipid peroxidation upon oxidant conditions (Bouvier
et al., 2009). Accordingly, 22:6/22:6-BMP, being very prone to
peroxidation, could exert oxidant action within its close environ-
ment, in particular toward cholesterol, then oxysterols are
deleterious to the cells (Hullin-Matsuda et al., 2009).
Acid sphingomyelinase (ASM; EC 3.1.4.12) is a glycoprotein,
being crucial for the pathogenesis of the rare, recessively inherited
lysosomal storage disorder, Niemann–Pick disease (type A and
type B). Secondary to sphingomyelin storage, many other lipids
such as cholesterol and gangliosides accumulate within lysosomes,
leading to a plethora of abnormalities in the cell function
(Schuchman, 2010). ASM is one of a family of enzymes that
catalyzes breakdown of sphingomyelin to produce ceramide by
cleavage of the phosphorylcholine linkage (Fig. 6b). It is crucial for
the normal membrane turnover, the integrity of lysosomes, and for
the ceramide-related signaling. ASM fulﬁlls a dual role—it has an
essential housekeeping function within the lysosomes and late
endosomes, whereas it has an important role for the activation of
apoptotic signaling at the cell surface (Smith and Schuchman,
2008). Accordingly, it is likely that activation of ASM at the cell
surface leads to apoptosis (Smith and Schuchman, 2008), whereas
inactivation of ASM within lysosomes leads to necrosis (Yama-
shima, 2012). In internal vesicles and membranes of lysosomes,er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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Fig. 6. The lysosomal membrane-stabilizing effect of Hsp70.1, and Ab-induced permeabilization of the multivesicular body (MVB). (a) When recombinant Hsp70 is added to
cancer cells, it is transported into the lysosome, then interacts with bis(monoacylglycero)phosphate (BMP); a membrane-bound, anionic phospholipid. The Hsp70–BMP
interaction (red circle) enhances association of BMP with acid sphingomyelinase (ASM: EC3.1.4.12), which can activate this enzyme so that ASM breaks down sphingomyelin
to generate ceramide. Although the exact role of ceramide remains to be determined, the increased production of ceramide by cascade d to e in lysosomes protects lysosomal
membranes from destabilization/rupturing. Please, note that BMP is localized not at the lysosomal limiting membrane but at the internal membranes. Late endosome (yellow
circle) is consistent with MLBs shown in Figs. 1b and c, 2c and 7b (cited from Horva´th and Vı´gh, 2010). (b) ASM catalyzes breakdown of sphingomyelin by cleavage of the
phosphorylcholine linkage, thereby producing a bioactive lipid, ceramide (cited from FASEB J 22, 3419–3431, 2008). (c) After adding freshly dissolved Ab1–40 peptide to the
medium, the cell culture system of J774A.1 cells (murine mononuclear phagocytes) reproducibly leads to the formation of an Ab plaque. By the transmission electron
microscope observation of freeze-fractured replica, immunogold labeling (arrows) shows that internalized Ab peptides become sorted to the MVB where amyloid ﬁbrils grow
out, thus penetrating the vesicular membrane (arrows; please, compare with Figs. 1c and 2c). Ultimately, these events lead to death of the affected cell, and intracellular Ab
peptides are released into the extracellular space to form an Ab plaque. A similar mechanism can be applied for the AD brain. MVBs are essentially consistent with late
endosomes/lysosomes. MVB: multivesicular body, V: other vesicular structures, Mit: mitochondria, ER: endoplasmic reticulum, Cyt: cytoplasm (cited from ProNAS 107,
1942–1947, 2010).
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isoelectric point of around 6.8, it possesses positively-charged
regions in the acidic lysosomal environment. These contribute to
the interaction of ASM with the anionic membrane-bound BMP
(Ko¨lzer et al., 2004; Schulze et al., 2009). After activation by
binding with BMP, ASM hydrolyzes sphingomyelin to ceramide
(Fig. 6a,b), and this activity depends on its recruitment to the intra-
lysosomal vesicular membranes by BMP through its saposin
domain (Jenkins et al., 2009). With the vesicle on one side and the
glycan part on the other side, lysosomal proteins such as ASM and
acid ceramidase are protected from the degradation by cathepsins
(Schulze et al., 2009). When the ASM-BMP interaction is disturbed,
the ASM displaced from its membrane-bound lipid substrate is
proteolytically degraded by lysosomal proteases (Ko¨lzer et al.,
2004).
Ceramide serves as a backbone of more complex sphingolipids
such as sphingomyelin and glycosylceramide. There are two
metabolic pathways leading to ceramide; the de novo pathway and
the salvage pathway (Gro¨sch et al., 2012). In ER, ceramide is
produced from sphinganine and acyl-CoAs (precursors and
intermediates in the sphingolipid biosynthesis pathway) by the
action of ceramide synthase (CerS), and transferred to the Golgi
apparatus or plasma membranes (the de novo pathway). InPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneuroblysosomes, sphingomyelin, the most abundant sphingolipid in the
brain, is metabolized by ASM to generate phosphocholine and
ceramide (the salvage pathway). There are two primary types of
sphingomyelinase with distinct subcellular localization; acid
sphingomyelinase cleaves sphingomyelin being located within
lysosmes and ER (Monney et al., 1998), while neutral sphingo-
myelinase cleaves sphingomyelin at the plasma membranes
(Veldman et al., 2001). CerS catalyzes the acetylation of sphingo-
sine with an activated fatty acid to form ceramide.
Among 6 types of CerS, CerS1 and CerS2 are responsible for the
production of C18 (C18:0 and C18:1) and C24 (C24:0 and C24:1)
ceramides, and both appear to be the most important ceramide
synthases in the CNS. CerS1 is highly expressed in most neurons
and important for the normal neuronal development, whereas
CerS2 is essential for the synthesis of myelin by oligodendrocytes
(Gro¨sch et al., 2012). Accordingly, changes in ceramide levels may
be closely related to various neurodegenerative disorders in
humans. Cutler et al. (2004) have shown in the AD brain that C18:0
and C24:0 ceramides are elevated in the middle frontal gyrus being
associated with extensive Ab plaques and tangles, and this
correlates with disease progression and severity. However, since
ceramide levels increase when autophagy is induced by oxidative
stresses, and the levels of C18:0 and C24:0 ceramide in cultureder’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
io.2013.02.004
Fig. 7. Normal and impaired macroautophagy, and formation of autophagic vacuoles. (a) The AD-related protein, presenilin 1 (PS1) is essential for the lysosomal acidiﬁcation
and protein degradation, because v-ATPase V0a1 subunit glycosylation and trafﬁcking to lysosomes requires PS1. In normal cells (WT), PS1 mediates the post-translational
addition of an N-glycan (rectangle) to the immature V0a1 subunit through interaction with the oligosaccharyltransferase (OST) complex and the translocon. Then, v-ATPase
contributes to sufﬁcient acidiﬁcation (pH 4.5) of lysosomes, and autophagosomes (AP) fuse with acidiﬁed lysosomes (Lyso) (called ‘maturation’) to promote degradation of
the autophagosome’s contents within autolysosomes (AL). In contrast, neurons in PS1-knock-out mice (PS1KO) show glyscosylation impairment in ER and lysosomal
acidiﬁcation deﬁcits (pH 5.7), thereby interfering with the subsequent autophagosome clearance during macroautophagy, and causing virtually complete failure of
macroautophagy and accumulation of autophagic vacuoles (AV being consistent with MVBs, red circle) (cited from Cell, 141, 1146–1158, 2010). (b) In AD neurons associated
with impaired lysosomal proteolysis, impairment of autophagy leads to massive accumulation of autophagic vacuoles called granulo-vacuolar degenerations (black arrows)
which means accumulation of incompletely degraded proteins in autolysosomes. Some autophagic vacuoles comprise of aggregates of microvesicles (yellow circle) as shown
also by electron microscopy (Fig. 2c). Robust autophagic vacuole accumulation precedes neuron death.
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2004), it is not clear whether the above elevation is a consequence
of Ab elevation or the cause of AD.
Incorporation of ceramide into membrane can increase its
rigidity by ordering the acyl chains, dividing the membrane into
microdomains (rafts/caveolae), promoting membrane permeabili-
ty and channel formation, facilitating membrane fusion and
inducing ﬁssion, budding and vesicle formation (Gro¨sch et al.,
2012). For instance, ceramide protects the lysosomal membrane
from rupturing (Fig. 6a) (Kirkegaard et al., 2010; Petersen et al.,
2010; Petersen and Kirkegaard, 2010), because the increased
concentration of lysosomal ceramide possibly facilitates fusion of
lysosomes with other intracellular vesicles and cell membranes
(Heinrich et al., 2000). Since generation of ceramide greatly alters
the membrane properties, increase in lysosomal ceramide content
might in itself have a positive impact on the lysosomal membrane
stability (Petersen et al., 2010; Petersen and Kirkegaard, 2010). In
addition to its structural role in the lysosomal membrane,
ceramide acts as a second messenger in various signaling pathways
at the plasma membranes. Ceramide can promote differentiation,
proliferation, death or survival (Billis et al., 1998; Andrieu-Abadie
et al., 2001), depending on cell type, mode (de novo or catabolic
reaction), subcellular location, and its chain length (Diringer et al.,
1972; Cutler et al., 2004). One should note that all ceramides are
not created equal, and ceramides likely exert distinct effects in
different cellular/subcellular compartments by virtue of access to
distinct molecules (Jenkins et al., 2009). The exact role of ceramidePlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobin neuronal survival or death still remains controversial and should
be elucidated further.
4. Impaired autophagy due to cleavage of lysosomal guardian
Hsp70.1
4.1. Autophagy failure leading to autophagic vacuoles
Proteolysis has been an active area of AD research over the past
two decades. In neurons, two proteolytic systems are mainly
responsible for the turnover of proteins and organelles: one is the
ubiquitin-proteasome system while another is the autophagic-
lysosomal systems (Goldberg, 2003; Ihara et al., 2012). The former
is responsible for degrading soluble proteins (mainly those with
short half-lives), whereas the latter is primarily responsible for
clearing insoluble protein aggregates and cellular organelles
(mainly those with long half-lives). For the postmitotic cell,
neurons, which cannot dilute toxic protein build-up by cell
division, the autophagic-lysosomal system is indispensable to sort
and clear damaged proteins and facilitate vital signaling functions.
Especially for the aged neurons, their survival depends on
eliminating a growing burden of long-lived, oxidized, aggregated,
or potentially toxic proteins and degrading, dysfunctional,
unwanted organelles.
Two pathways of endocytic (Fig. 6a) and autophagic (Fig. 7a)
share in common the role of delivering unneeded cellular materials
to lysosomes for recycling to provide new synthesis and energy.er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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tic transmission and plasticity that proceed in synaptic terminals
at great distances from the perikaryon. Endosome abnormalities,
being closely related to the synaptic loss and memory disorders,
are the earliest speciﬁc events in the AD brain. Neuronal endosome
enlargement, speciﬁc for AD, develops in pyramidal neurons of the
neocortex at a stage when plaques and tangles are restricted only
to the hippocampus (Cataldo et al., 2000; Ihara et al., 2012).
Autophagy is lysosome-mediated catabolic mechanism, which
plays an important role to maintain cellular homeostasis by
continually recycling cellular components for the biosynthesis and
energy production. It is deﬁned as the lysosomal digestion of a
cell’s own material such as damaged cytoplasmic components and
organelles. For example, lower eukaryotic organisms such as yeast
can survive nutrient starvation conditions by degrading non-
essential cell constituents to utilize as an energy source. The same
may occur in the mammalian cells when facing the severe stresses
such as nutrient deprivation, hypoxia, heat, irradiation, etc.
Autophagy is classiﬁed into three processes by which intracel-
lular constituents reach the lumen of lysosomes for degradation:
chaperone-mediated autophagy, microautophagy, and macroau-
tophagy (Cuervo, 2004; Mizushima et al., 2008; Levine et al., 2011).
All autophagic vacuoles eventually fuse with lysosomes which
provide hydrolases as degradating enzymes. In chaperone-
mediated autophagy, cytosolic proteins such as APP and synuclein
containing a KFERQ motif are selectively targeted to the lysosomal
lumen for degradation. For example, the processing of tau occurs
partially by chaperone-mediated autophagy. Upon association of
tau with the lysosomal limiting membrane via heat-shock
constitutive protein 70 (Hsc70) and lysosome-associated mem-
brane protein-2a (lamp-2a), tau is translocated into the lumen of
lysosomes thereby allowing proteolysis by cathepsins (Wang et al.,
2009; 2010). In microautophagy the lysosome invaginates its own
membrane to uptake segments of the cytoplasm (Massey et al.,
2004; Nixon, 2006; Kragh et al., 2012). Macroautophagy, being
conserved from yeast to mammals, is the principal degradative
pathway necessary for the aged or oxidatively-damaged organelles
and long-lived proteins. It is primarily a protective process for
neurons, and impaired clearance of autophagic vacuoles by
macroautophagy may be closely related to neurodegeneration in
AD (Cardoso et al., 2010).
In macroautophagy, regional sequestration of cytoplasm within
an enveloping double membrane structure (pre-autophagosomal
membranes), creates vacuoles designated autophagosomes that
are continuously generated at the distal ends (synapses) of axons
or dendrites (Fig. 5a) (De Duve and Wattiaux, 1966; Klionsky et al.,
2008). Newly formed autophagosomes are normally eliminated
efﬁciently in neurons by fusing with lysosomes or late endosomes
to form autolysosomes, because such fusion being called
‘maturation’ can provide hydrolases necessary for degaradation
(Boland et al., 2008; Noda et al., 2009). Then, both lysis of the
autophagosome inner membrane and breakdown of the contents
occur within autolysosomes (Fig. 7a) (Mizushima et al., 2008). For
achieving this, autophagosomes must travel retrogradely long
distances before being efﬁciently degraded by fusing with
lysosomes which usually concentrate in or near the perikaryon
(Fig. 5a) (Nixon et al., 2005; Nixon, 2007). Accordingly, intact
microtubules are needed (Fig. 5b) for the trafﬁcking of endosomes
or autophagosomes, which facilitates their fusion with lysosomes
at the destination (Kova´cs et al., 1982; Ko¨chl et al., 2006). Such
autophagic pathway is constitutively active and highly efﬁcient in
neurons, and is essential for the neuronal survival. Since cytosolic
tau and proteolytic products can be degraded by macroautophagy
(Dolan and Johnson, 2010; Wang et al., 2010), its impairment
results in accumulation and further aggregation of tau (Hamano
et al., 2008). Accordingly, dysfunction of tau proteolysis in ADPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobneurons conceivably leads to accumulation of tau fragments that
are prone to aggregation (van Echten-Deckert and Walter, 2012).
Multivesicular bodies (MVBs), showing ﬁngerprint-like struc-
tures, are vesicular organelles morphologically deﬁned by a
limiting membrane and characteristic inner vesicles at the
ultrastructural level (Figs. 1b and c, 2c and 8b: yellow circles),
and considered a sorting compartment within the endocytic
pathway (Gruenberg, 2001). Both early endosomes and, more
typically, late endosomes (Fig. 6a: yellow circles) have been
described as MVBs (Gruenberg and Maxﬁeld, 1995; Katzmann
et al., 2001). When early endosomes mature into late endosomes,
regions of the surface membrane bud off into the endosome lumen
to form more MVBs (van der Goot and Gruenberg, 2006). MVBs are
involved in the regulated trafﬁcking of several proteins and
membrane receptors (Gruenberg and Stenmark, 2004). For
example, after endocytosis of APP from the plasma membrane
(Koo and Squazzo, 1994), internalized APP trafﬁcs from the plasma
membrane to MVBs (Fig. 6c) (Yamazaki et al., 1996; Friedrich et al.,
2010). Then, Ab is generated via consecutive cleavage by b-Site
APP cleaving enzyme (BACE) (Vassar et al., 1999) at endosomal
vesicles (Huse et al., 2000) and g-secretase in late endosomes
(Vetrivel et al., 2005).
MVBs can be identiﬁed not only in the normal neurons but also
in the AD neurons (Takahashi et al., 2002). Mounting evidence
shows that failure of the substrate proteolysis within autolyso-
somes causes increased formation and accumulation of autophagic
vacuoles (Figs. 1b and c, 2c and 7a and b) (Nixon et al., 2005; Nixon,
2006, 2007; Nixon and Yang, 2011). At the electron microscopic
observation autophagic vacuoles often look like MVBs, because
lipid components are more efﬁciently preserved by the glutaral-
dehyde and osmium ﬁxation compared to the formalin ﬁxation for
light microscopy (Figs. 1b and c and 2c: yellow circles). In both APP
mutant transgenic mice and human AD brains, progressive
accumulation of Ab42 occurs in neuronal MVBs (Takahashi et al.,
2002), and Ab accumulation impairs multivesicular body sorting
by inhibiting the ubiquitin-proteasome system (Almeida et al.,
2006). Then, the ordered MVB function is disturbed and some Ab
ﬁbrils grow out, thus penetrating the vesicular membrane (Fig. 6c,
arrows) (Friedrich et al., 2010). When degenerating neurons die
ultimately, intracellular amyloid peptides are released into the
extracellular space to aggregate each other, consequently forming
senile plaques (Fig. 1a). Accordingly, extracellular Ab plaques
contain a spectrum of proteins that were originally intracellular.
For instance, Ab plaques commonly contain lysosomal proteases
like cathepsin D or molecular chaperones like Hsp70 or Hsp20
(Cataldo and Nixon, 1990; Roher et al., 1993; Wilhelmus et al.,
2007). Since Ab42 accumulates in MVBs within presynaptic and
especially postsynaptic compartments (Takahashi et al., 2002;
Langui et al., 2004), Alzheimer transgenic mice show impaired
synaptic plasticity and learning, as Ab levels rise, months before
the appearance of Ab plaques (Chapman et al., 1999).
During clearance of autophagosomes, fusion with lysosomes
introduces more than 60 hydrolases into the autophagosomes. A
membrane-spanning proton pump, v-type [H+]-ATPase (v-
ATPase), lowers the intralumenal pH to the level optimal for the
protease activation (Sun-Wada et al., 2003). However, lysosomal
destabilization would affect downstream autolysosome formation
and abolish supply of metabolic substrates provided by autophagy
(Repnik and Turk, 2010). Fusion with the destabilized lysosomes
may disturb clearance of autolysosomes, consequently autophagic
vacuoles are formed and accumulate (Fig. 7a). In Caenorhabditis
elegans, autophagy synergizes with lysosomal proteolytic path-
ways to facilitate necrosis, and excessive autophagosome forma-
tion is induced early during necrotic cell death (Samara et al.,
2008). Similar situations can be observed in programmed neuronal
necrosis in AD; for example, autophagic dense vesicles (Fig. 1b) orer’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
io.2013.02.004
Fig. 8. Electron microscopic photographs showing impairments of lysosomal integrity and maturation in the degenerating AD neuron. In affected neurons of AD, newly
formed autophagosomes are not efﬁciently cleared by fusion with lysosomes. Accordingly, the perikarya of the degenerating neuron containing neuroﬁbrillary tangle (a; long
arrow) is ﬁlled with autophagic vacuoles containing multilamellar bodies (b; long arrows). It is conceivable that multilamellar bodies derive from the endocytosis of plasma
membranes while non-lamellar lysosomes derive from autophagy of non-membranous organelles. The degenerating neuron shows a remarkable decrease of mitochondria,
ER and free ribosomes. There are three types of lysosomes; one with an electron-dense core being surrounded by the distinct limiting membrane (b: arrowheads), another
with double-contours (a, b: red rectangles), and the other containing many vesicles being reminiscent of MVBs (b: yellow circles). Double contour of the lysosome (a, b: red
rectangles) appears to have lost its delimiting membrane due to the destabilization and/or partial rupture, and shows a contrast with the vivid lysosomes (b, arrowheads).
Black rectangle in a is magniﬁed in b, while red rectangle in b is magniﬁed in a. N: nucleus (cited from J Neuropathol Exp Neurol 64, 113–122, 2005).
T. Yamashima / Progress in Neurobiology xxx (2013) xxx–xxx 13
G Model
PRONEU-1261; No. of Pages 23autophagic vacuoles (Figs. 1c and 7b) accumulate in dystrophic
neurites or perikarya of degenerating neurons, respectively (Nixon
et al., 2005), probably due to impairment of autophagosome
maturation into autolysosomes (Fig. 7a) (Yu et al., 2005). However,
the molecular basis for the autophagosome clearance by lysosomes
(i.e. maturation) and/or the profuse accumulation of autophagic
vacuoles in the AD-affected neurons has not been clariﬁed
completely. Accordingly, until recently one could not conclude
whether the autophagy per se constitutes an independent pathway
of programmed neuronal death or merely one of the downstream
manifestations of a much more complex process (Yuan et al.,
2003). Even now, no one can conclude whether impaired clearance
of autolysosomes and/or accumulation of autophagic vacuoles are
contributing to neuronal death or protecting against it. Interest-
ingly, autophagosomes were found to accumulate relatively
rapidly when their clearance was prevented by blocking lysosomal
degradation with cathepsin inhibitors in primary cortical neurons
(Boland et al., 2008). Defective clearance, i.e. accumulation of
autophagosomes associated with the lysosomal depletion was
conﬁrmed in the degenerating dopaminergic neurons of the
Parkinson’s disese patients and its animal models (Dehay et al.,
2010). Furthermore, studies on various lysosomal storage dis-
orders revealed evidence of impaired clearance of autophagic
vacuoles (Kiselyov et al., 2007; Settembre et al., 2008). Taken
together, it is most probable that accumulation of autophagic
vacuoles via lysosomal destabilization leads to neuronal death.
4.2. Congenital or acquired mechanisms of autophagy failure
Mutations in the presenilin genes are known to be the common
cause of familial AD. Presenilin is the catalytic subunit of the g-
secretase activity that liberates Ab peptide from the C-terminus of
APP (Wakabayashi and De Strooper, 2008). The pathogenic effects
of presenilin 1 mutations in AD are commonly ascribed to
increased generation of the neurotoxic Ab peptide from APP.
Furthermore, presenilin 1 is crucial for the subcellular membranePlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobtrafﬁcking (Esselens et al., 2004; Wilson et al., 2004; Sannerud and
Annaert, 2009), and is required for the lysosomal turnover of
autophagic and endocytic protein substrates. Disruption of the
autophagy pathway promotes depositions of amyloid plaques
(Pickford et al., 2008; Tooze and Schiavo, 2008). In addition, more
importantly, presenilin 1 is essential for targeting of v-ATPase V0a1
subunit to lysosomes to maintain lysosomal acidiﬁcation neces-
sary for the proteolysis during autophagy (Fig. 7a) (Yoshimori et al.,
1991; Lee et al., 2010). Presenillin 1 mutations cause impaired
autophagy as a result of a selective impairment of autolysosome
acidiﬁcation and cathepsin activation, which may affect neuronal
survival (Lee et al., 2010).
In the familial AD, mutant presenilin 1 disrupts autophagy by
impeding lysosomal acidiﬁcation (Fig. 7a). Then, such a question
emerges how autophagy failure occurs in the majority of AD cases
who are free from presenillin 1 mutations. The author speculates
that impaired autophagy in AD also arises from impaired clearance
of autophagosomes due to the age-related Hsp70.1 dysfunction.
The latter induces both (1) the failure of maturation process (i.e.
trafﬁcking of autophagosomes in the synaptic and dendritic area to
lysosomes in the perikarya) (Fig. 5a), and the resultant (2)
autolysosomal proteolytic failure by its inappropriate acidiﬁcation
that leads to autophagic vacuole accumulation (Fig. 7a). It is
noteworthy that both failure can occur by the carbonylation and
cleavage of key molecule ‘Hsp70.10 (Fig. 4) in the sporadic AD
patients who are free from presenillin 1 mutations. In the most
common, sporadic AD, impaired autophagy can be explained by
calpain-mediated cleavage of carbonylated Hsp70.1 that causes
ASM dysfunction (Fig. 4 c,d,e, 6a) (Yamashima, 2012). The binding
of normal Hsp70.1 with BMP regulates the enzyme activity of ASM
which generates ceramide for the lysosomal membrane stabiliza-
tion. Accordingly, it is probable in the Alzheimer brain that HNE-
induced carbonylation of Hsp70.1 and calpain-mediated cleavage
of the carbonylated Hsp70.1 (Sahara and Yamashima, 2010), might
cause down-regulation of BMP and ASM activities, which leads to
storage of sphingomyelin with the resultant lysosomal dysfunctioner’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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autophagy failure but also defective microtubular trafﬁcking by
inhibiting kinesin-dependent fast axonal transport (Fig. 5b)
(Patterson et al., 2011b).
Multilamellar bodies (or myeloid bodies) are ultrastructurally
composed of concentric membrane layers with an electron-dense
core (Fig. 8b), but reveal as autophagic vacuoles on light
miscroscopy (Fig. 7b). Lysosomal nature of them has been
demonstrated by the presence of various lysosomal enzymes
(Hariri et al., 2000), and they form during the endocytic pathway of
plasma membranes (phosphilipid-like sphingomyelin) under both
physiological and pathological conditions. For example, multi-
lamellar bodies are responsible for the surfactant secretion in type
II alveolar cells to prevent alveolae from collapse during
respiration but also accumulate in other cell types under
pathological conditions such as lysosomal storage diseases (Lajoie
et al., 2005). As neuronal survival requires continuous lysosomal
recycling or turnover of cellular constituents, lysosomal destabili-
zation causes severe lipidosis, i.e. accumulations of multilamellar
bodies (Fig. 8) (Yamashima, 2012). Macroautophagy is sensitive to
the phosphatidylinositol 3 (PI 3)-kinase inhibitor, 3-methylade-
nine (Seglen and Gordon, 1982; Blommaart et al., 1997). Serum
starvation stimulates macroautophagy in various cell lines
(Munafo´ and Colombo, 2001; Susan and Dunn, 2001), then such
stimulation of macroautophagy is associated with increased size
and concentric lamellar morphology of multilamellar bodies
(Hariri et al., 2000; Lajoie et al., 2005). The formation of
multilamellar bodies starts with inward budding of the limiting
endosomal membrane and requires the sequential action of three
endosomal sorting complexes required for transport (ESCRT-I, -II, -
III) (Hopkins et al., 1990). They are found in numerous cell types
where they function in lipid storage and secretion (Schmitz and
Mu¨ller, 1991).
Drug-induced phospholipidosis is an artiﬁcial phospholipid
storage disorder that is characterized by the excessive accumula-
tion of multilamellar phospholipids in tissues (Tengstrand et al.,
2010). For example, excess intake of drugs such as tetracyclines
and anti-histamines cause phospholipidosis in the renal cortex.
Similarly, numerous multilamellar bodies can be detected in the
urinary sediment of patients with acute renal failure receiving
gentamycin. The accumulation of undigested drug-phospholipid
complexes and an alteration in lysosomal enzyme activity results
in the intracellular accumulation of multilamellar bodies. It may
have an adaptive or detoxiﬁcation effect by sequestering and
eliminating drugs and their metabolites from the cell (Tengstrand
et al., 2010). Putative b1–6 branching and polylactosamine
glycosylation of multilamellar body glycoproteins might enhance
their resistance to degradation by lysosomal proteases or modify
interactions between the lamellar components, thereby favoring
lamella formation (Hariri et al., 2000). Initially, single or multiple
foci of lamella appear within an autophagic vacuole, which
transform into multilamellar structures. Treatment of the lung
type II alveolar cells with leupeptin, an inhibitor of many lysosomal
proteases, results in the progressive transformation of the multi-
lamellar bodies into electron-dense autophagic vacuoles and
eventual disappearance of these bodies. In contrast, treatment
with 3-methyladenine, an inhibitor of autophagic sequestration,
results in the signiﬁcantly reduced expression of multilamellar
bodies and the accumulation of inclusion bodies resembling
nascent or immature autophagic vacuoles (Hariri et al., 2000).
These data indicate that the selective impairment of lysosomal
degradation is indispensable for the formation of multilamellar
bodies.
Intriguingly, autophagic vacuoles containing multilamellar
bodies can be seen in various situations such as congenital and
drug-induced lysosomal storage diseases (Lajoie et al., 2005;Please cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobTengstrand et al., 2010), Alzheimer disease (Nixon et al., 2005),
Niemann-Pick disease (Macauley et al., 2008; Saunders and
Wenger, 2008), and cerebral ischemia (Yamashima, 2012).
Accordinly, it is likely that not only congenital impairment of
the lysosomal acidiﬁcation but also acquired disorders of
lysosomal factors including Hsp70.1, BMP, ASM, etc. would cause
formation of autophagic vacuoles (Figs. 1, 2c, 7b) and/or multi-
lamellar bodies (Fig. 8) as a result of impaired autophagy and
lysosomal lipidosis in AD neurons.
5. Evidence of lysosomal rupture in vitro and in vivo
Brunk and his colleagues established the concept of lysosomal
membrane permeabilization (LMP) in a series of works using
cultured cells undergoing artiﬁcial oxidative stresses (Brunk et al.,
1997; Brunk and Svensson, 1999; Li et al., 2000; Antunes et al.,
2001; Ka˚gedal et al., 2001). Taken together with the monkey data
of the author’s group (Yamashima et al., 1996, 1998), it became
clear that low levels of stress cause LMP and apoptosis, whereas
high levels of stress cause lysosomal rupture and necrosis (Bursch,
2001; Nylandsted et al., 2004; Kirkegaard and Ja¨a¨ttela¨, 2009; Turk
and Turk, 2009). LMP was suggested to induce apoptosis by
mitochondrial transmembrane potential loss or caspase activation.
In contrast, lysosomal rupture can induce necrotic cell death due to
extensive leakage of cathepsin enzymes (Tardy et al., 2006). There
are cross-talks among cellular organelles (Ferri and Kroemer,
2001), especially between lysosomes and mitochondria (Repnik
and Turk, 2010; Repnik et al., 2012), as well as between apoptosis
and necrosis cascades (Yamashima, 2000).
Lysosomal cathepsins B and L as well as cathepsin D (Fig. 9a)
released into the cytoplasm may damage cellular constitutive
proteins and cytoskeletons. Simultaneously, they damage the
lysosomal membrane from outside, or activate phospholipases
that degrade all types of cellular membranes. Furthermore, they
attack mitochondria to cause release of cytochrome c and other
pro-apoptotic factors from outer membranes, and also to induce
more H2O2 production by interfering with the mitochondrial
electron-transporting complexes (Terman et al., 2006). The
hypothesis that lysosomal leakage of cathepsin B into the
cytoplasm causes apoptotic cell death would be even more
persuasive, if considering data of cathepsin B knockout mice
and inhibitor experiments. For example, using cathepsin B
knockout mice, Guicciardi et al. (2000) showed that cathepsin B
is critical to TNF-a-mediated hepatocyte apoptosis, while House-
weart et al. (2003) showed that it is the principle cause of apoptotic
cell death in an epileptic animal model. Furthermore, Foghsgaard
et al. (2001) showed that cathepsin B is the dominant execution
protease in tumor cell apoptosis, using cathepsin B inhibitors in
ﬁbrosarcoma cells. Luo et al. (2010) also showed that the cathepsin
B inhibitor CA-074Me reduced the proapoptotic biomarkers such
as Bax, reduced neuronal cell death, and improved memory deﬁcits
in a traumatic brain injury model. In addition, both cathepsin D and
cathepsin L being released from lysosomes, can induce the
proteolytic activation of Bid, and this generates a truncated Bid
that causes release of cytochrome c from mitochondria and
activation of caspases-9 and caspase-3 (Stoka et al., 2001; Heinrich
et al., 2004).
Until now, intriguingly, very little is known about the exact role
of Ab in the development of Alzheimer neuronal death. Yang et al.
(1998) demonstrated in the neuroblastoma SH-SY5Y cells that
failure of degrading aggregated Ab1–42 in the endosomal/
lysosomal compartment causes loss of lysosomal membrane
integrity (Fig. 9b-e). Actually, the cultured SH-SY5Y cells can
internalize soluble Ab1–42 from the culture medium, which
accumulate inside the endosomal/lysosomal system. However,
the intracellular Ab1–42 is resistant to protease degradation ander’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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Fig. 9. In vivo and in vitro evidence of the lysosomal destabilization, and synergic action of Ab1–42 and apoE4 for the lysosomal destabilization and DNA fragmentation. (a) The
cytoplasmic cathepsin D (CatD) immunoreactivity is more intense in AD neurons, compared to the age-matched controls (Cont). This indicates extra-lysosomal release of the
cathepsin D enzymes, presumably due to the lysosomal destabilization as shown in Fig. 8 (red rectangles) (cited from Cold Spring Harb Perspect Med 2, a006361). (b and c)
Lucifer yellow is the ﬂuid-phase endocytic tracer dye. When SH-SY5Y cells are loaded with this vital dye, it is terminally trafﬁcked to the lysosomes. In the control cells
without Ab1–42, lucifer yellow-positive lysosomes are distributed in a punctate, perinuclear fashion (b). After incubation with Ab1–42, the lysosomal membranes
synchronously begin to leak, then lucifer yellow shows a diffuse distribution in the cytoplasm (c). (d and e) Cathepsin D (CatD) is also abnormally redistributed in Ab1–42-
treated SH-SY5Y cells. In the control cells, cathepsin D displays typical, perinuclear, granular endosomal/lysosomal immunostaining (d). In contrast, Ab1–42-treated cells
display both cytoplasmic and granular immunostaining, which indicates lysosomal destabilization by Ab1–42 (e) (cited from J Neurosci Res 52, 691–698, 1998). (f)
Comparison of Ab-induced lucifer yellow leakage among three types of Neuro-2a cells; Neo-, apoE3-, and apoE4-secreting cells. The largest leakage occurs in apoE4 cells
when incubated with wild type Ab or Arctic Ab. However, there were no difference of increment in response to the more soluble GM6 Ab. Control cells; incubated without
Ab1–42, Wild type Ab: incubated with Ab1–42, GM6 Ab1–42; incubated with the GM6 mutated (F690S/L705P) Ab being engineered to resist aggregation, Arctic Ab; incubated
with ‘Arctic’ mutated (E693G) Ab enhancing aggregation in vitro. (g) Effect of increasing concentrations of exogenous human apoE (0–15.0 mg/ml) with Ab on DNA
fragmentation of Neo-transfected Neuro-2a cells. When compared with apoE3 (white bar), apoE4 (black bar) signiﬁcantly provoked Ab1–42-induced DNA fragmentation in
proportion to the apoE4 concentrations. *p < 0.05; **p < 0.01; ***p < 0.001 versus Ab alone without exogenous apoE4 (cited from J Biol Chem 281, 2683–2692, 2006).
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disruption of lysosomal membrane proton gradient, and eventu-
ally lysosomal rupture. The latter provokes leakage of cathepsin D
or lucifer yellow (Fig. 9e,f) into the cytoplasmic compartment. As
treatment of cells with antioxidants partially blocks the release of
lysosomal contents, the disruption of lysosomal membrane
integrity may be caused by oxidative damage to the lysosomal
membrane lipids rather than by the direct solubilization of
lysosomal membrane by Ab (Ditaranto et al., 2001). It is probable
that Ab can cause Alzheimer neuronal death not by direct effects
upon lysosomal membranes but by indirect effects down-
regulating lysosomal factors.
In the AD brain, microglia play a central role in mediating chronic
inﬂammatory conditions by releasing numerous acute phase
proteins such as a-antichymotrypsin, a-antitrypsin, complement
proteins, and proinﬂammatory cytokines such as interleukins 1a,
1b, and 6, tumor necrosis factor (TNF)-a, etc. (Klegeris et al., 1997;
McDonald et al., 1997; Licastro et al., 1998; Yates et al., 2000;
Veerhuis et al., 2003). Because activated microglia are intimately
related to senile plaques, and NSAID show protective effects (Rich
et al., 1995; McGeer et al., 1996; Stewart et al., 1997; In t’Veld et al.,
2001; Mackenzie and Munoz, 1998, 2001; Zandi et al., 2002), chronic
inﬂammation has been thought to play an important role in AD
pathogenesis. Besides ﬁbrillar Ab1–42, soluble Ab1–42 also appears to
be a potent activator of microglia. Using a functional genomics
approach to ﬁnd crucial molecular mediators, Gan et al. (2004) found
554 upregulated genes being transcriptionally induced by Ab1–42,Please cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneuroband identiﬁed cathepsin B as one of the key players in the neurotoxic
effects that were caused by freshly sonicated Ab1–42-activated
microglial BV2 cells. Freshly sonicated Ab1–42 did not cause
neuronal death when added directly to primary cultured neurons,
but activated BV2 cells releasing cathepsin B caused remarkable
neuronal death. Not only small interfering RNA-mediated silencing
of the cathepsin B gene but also cathepsin B inhibitor CA-074
diminished the activated microglia-mediated neurotoxicity. Ac-
cordingly, cathepsin B released from the activated microglia into the
medium was also thought to play an essential role in neuronal death
mediated by Ab-activated inﬂammatory response. Regardless of the
cellular origin of cathepsin B, extra-lysosomal release of this
protease has a crucial role in the development of Alzheimer
neuronal death.
Lysosomal or endosomal abnormalities were thought to be one
of the causative factors of AD (Cataldo and Nixon, 1990; Nixon
et al., 1992; Cataldo et al., 1995). In the normal brain, most Ab
being formed during autophagy is degraded properly within
lysosomes. On the contrary, in the Alzheimer brain, Ab initially
accumulates within lysosomes and late endosomes, and is
subsequently trafﬁcked into the large pool of autophagic vacuoles
that becomes a major intracellular reservoir of the toxic peptide
(Glabe, 2001; Yu et al., 2005). Intracellular amyloid induces
generation of ROS and lipid peroxidation products. Ab within
lysosomal compartments can trigger release of hydrolytic enzymes
into the cytoplasm, which causes cell death (Fig. 9) (Yang et al.,
1998; D‘Andrea et al., 2001; Ditaranto et al., 2001; Glabe, 2001;er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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neuron may ultimately lyse or die and release the insoluble Ab into
the extracellular space, where the cell debris and Ab may serve as a
nidus for the senile plaques (Fig. 1a).
Despite the numerous in vitro studies, the molecular mecha-
nisms of lysosomal membrane disruption have been poorly
understood in vivo until the ‘calpain–cathepsin hypothesis’ was
formulated from the ischemic monkey experimental paradigms
(Yamashima et al., 1998). Owing to the formulation of this
hypothesis, the cascade leading to lysosomal rupture and its effects
on ischemic neuronal death have become more clear, but
implication of lysosomal rupture in vivo still remains unclear in
the Alzheimer neuronal death. Because of the tininess of
lysosomes, it is usually difﬁcult to observe disruption of their
limiting membrane especially in the postmortem brain tissues.
Accordingly, for the assessment of lysosomal membrane integrity
in AD neurons by electron microscopy, one must be most careful
not to underestimate presence of LMP and/or lysosomal rupture. At
the careful observation, for instance, double contour of the
lysosome appears to have lost its delimiting membrane (Fig. 8:
red rectangles), showing a remarkable contrast with the normal
lysosome, and is reminiscent of permeabilization and/or rupture of
the limiting membrane. In the CA1 neurons after ischemia/
reperfusion, Yamashima et al. (1996, 1998) discovered direct
evidence of lysosomal membrane rupture by electron microscopy.
Simultaneously, immunohistochemical analysis showed that
cathepsins B and L were redistributed from lysosomes into the
cytosol and/or the neuropil. Similarly, in the neurons of human AD
patients, cathepsin D was redistributed from lysosomes into the
cytosol (Fig. 9a). As the extent of lysosomal destabilization is
distinct between ischemic neuronal death and Alzheimer neuronal
death, programmed neuronal necrosis presumably occurs within
days by the lysosomal rupture in acute ischemia while within years
by the lysosomal permeabilization in AD.
In the AD brain, cathepsin D immunoreactivity was often
localized extracellularly to the senile plaques (Cataldo and Nixon,
1990; Cataldo et al., 1995, 1996). In the rat brain, cathepsin D
showed an age-dependent signiﬁcant increase (Bi et al., 2000,
2003), while cathepsin L showed an age-related remarkable
reduction (Nakanishi et al., 1994). A similar increase in the
cathepsin D immunoreactivity associated with aging was found in
neurons of dogs (Lynch and Bi, 2003). Cathepsin D is also common
in the aged human brains, and shows a remarkable increase not
only in the vulnerable neurons of the AD brain in advance of the
onset of overt pathology (Cataldo et al., 1991; Troncoso et al., 1998;
Nixon et al., 2000) but also in the cerebrospinal ﬂuid of AD patients
(Schwagerl et al., 1995). As cathepsin D can perform a limited
proteolysis of a substrate even at physiological pH in the
extracellular medium (Lkhider et al., 2004), cathepsin D should
be active in vivo not only at very acidic pH but also at neutral pH.
Implication of cathepsin D for Alzheimer neuronal death is
reasonable, if considering the very slow progression of AD.
ApoE was present within a majority of plaques immunoreactive
for Ab with the exception of very small Ab deposits. In the senile
plaques, cathepsin D is capable of proteolyzing both lipid-free and
lipidated apoE to generate N-terminal and C-terminal fragments
that are similar in size to those found in the AD brain (Zhou et al.,
2006). As APP is extensively hydrolyzed by cathepsin D (Chevallier
et al., 1997; Malik et al., 2011), this protease can be involved in the
regulation of amyloid protein formation and play an important role
in the pathogenesis of AD. Cathepsin D, being effective at neutral
pH, can degrade cytoskeletal proteins such as neuroﬁlaments,
tubulin, and microtubule-associated proteins (Banay-Schwartz
et al., 1983, 1987; Nixon and Marotta, 1984; Matus and
Green, 1987; Johnson et al., 1991). Furthermore, cathepsin
D-mediated degradation of apoE with the capacity of detoxifyingPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobhydroxynonenal (Zhou et al., 2006) will facilitate HNE induced
carbonylation of Hsp70.1. In cultured Neuro-2a cells, Ji et al. (2002,
2006) demonstrated that apoE4, but not apoE3, potentiated
lysosomal leakage and DNA fragmentation (Fig. 9g), and the
lysosomal leakage was more induced by aggregated forms of Ab1–
42 peptide than the soluble form (Fig. 9f). This is presumably
because HNE being generated by Ab-induced oxidative stress was
not detoxiﬁed by apoE4, but by apoE3. Taken together, the
increased enzymal activity and co-localization of cathepsin D in
the apoE-positive senile plaques and neuroﬁbrillary tangles (Zhou
et al., 2006) may be closely related to neurodegenerative processes
in AD (Bernstein et al., 1989; Cataldo et al., 1990; Cataldo and
Nixon, 1990; Namba et al., 1991; Haas and Sparks, 1996; Metsaars
et al., 2003).
6. Preventive and therapeutic strategies against Alzheimer’s
disease
There are likely to be behavioral (irregular physical and mental
exercises, sedentary lifestyle), dietary (high-calorie, high-fat, high-
linoleic acid), and other environmental (irradiation, electromag-
netic waves, pollution) factors that may gradually affect the brain
health. Although a causal relationship between these factors and
AD occurrence has not been well established, the age-related
cerebral arteriosclerosis and the resultant, mild but long-standing
cerebral ischemia as well as concomitant oxidative stresses can
undoubtedly affect survival of neurons (Fig. 10). Cerebral ische-
mia- and/or Ab-induced calpain activation and ROS-induced HNE
generation, when combined together, cause Hsp70.1 carbonylation
and cleavage which ultimately lead to the lysosomal rupture.
Based on the ‘calpain–cathepsin hypothesis’, the author asserts such
a possibility that inhibitions of calpain or cathepsin activity is
likely to be an effective AD therapy. The administration of
pharmacological agents that prevent calpain before the onset of
AD course confers optimal neuroprotection. However, most
patients are treated decades after the onset, when considerable
numbers of hippocampal neurons have been already damaged by
activated calpain and oxidants. Therefore, the pharmacological
inhibition of post-calpain executioners of cell death; e.g. cathe-
psins B, L, or D might be more useful not to expand neuronal loss.
The efﬁcacy of cathepsin blockade in AD animal models would
greatly support that such therapy will be effective also for patients
with AD. For example, cathepsin B has been proposed as an
alternative candidate of b-secretase, because it produces Ab by
efﬁcient cleavage of the wild-type b-secretase site of APP (Hook
et al., 2005). Accordingly, deleting the cathepsin B gene in
transgenic mice expressing human APP containing the wild-type
b- and London mutant g-secretase site (APPLon) sequences,
caused a substantial reduction in brain Ab, reduced brain plaque
and improved memory deﬁcits (Hook et al., 2009; Kindy et al.,
2012). Moreover, administering the calpain–cathepsin inhibitor
E64-d (l-3-trans-carboxyrane2; the membrane permeable analog
of E64-c) (Murata et al., 1991; Towatari et al., 1991) to transgenic
APPLon mice also improved memory deﬁcits, by reducing brain Ab
and amyloid plaque, and providing potent neuroprotection (Hook
et al., 2008, 2011). This group found that eliminating or inhibiting
cathepsin B reduced brain Ab in animals expressing APP contain-
ing the wild-type b-secretase site sequence but had no effect on
animals expressing APP containing the Swedish mutant b-
secretase site sequence (APPSwe). That lack of effect on Ab in
APPSwe mice was conﬁrmed by Mueller-Steiner et al. (2006), but
Trinchese et al. (2008) showed that nonetheless E64-d produced
neuroprotective effects and improved memory deﬁcits in APPSwe
mice, being independent of Ab lowering effect. Accordingly,
irrelevant to Ab, cathepsin B appears to be an effective drug target
in most AD patients.er’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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Fig. 10. Flow-chart of the molecular mechanisms involved in Alzheimer neuronal
death. Neurons degenerating in AD exhibit perturbed cellular Ca2+ homeostasis,
increased generation of ROS and depositions of Ab due to the long-standing, mild
cerebral ischemia with aging. Although numerous lines of genetic and biochemical
evidence until now suggested that Ab is central to the pathogenesis of AD, Ab
appears to be merely one of the causative factors. Instead, the ‘calpain-mediated
cleavage of carbonylated Hsp70.10 appears to be crucial for the development of
Alzheimer neuronal death. Hydroxynonenal (HNE) is a membrane lipid-derived
neurotoxin that carbonylates Hsp 70.1 being indispensable for the lysosomal
stabilization. As the Hsp70.1-mediated activation of acid sphingomyelinase (ASM)
leads to an increment in ceramide for the membrane stabilization, it is probable in
the Alzheimer brain that carbonylation and cleavage of Hsp70.1 may cause decrease
of ASM activity and accumulation of sphingomyelin with the resultant lysosomal
rupture. The calpain–cathepsin cascade would be exaggerated in the presence of Ab
but can proceed even without Ab, and this can explain why AD occurs in those
without any Ab depositions in the brain. This cascade can reasonably explain
implications of all players characterizing AD, including HNE, apoE4, Ab, non-
steroidal anti-inﬂammatory drugs (NSAID), presenilin 1, and tau for the Alzheimer
neuronal cell death. For example, apoE4, the strongest genetic risk factor for the late
onset sporadic AD, accelerates toxicity of HNE because of failure of binding or
detoxiﬁcation. Implications of other players were described in detail in the text.
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reported by the author’s group in cerebral ischemia models
(Yamashima et al., 1998; Tsuchiya et al., 1999), and have been
discussed in various experimental paradigms (Ray et al., 2000; Wang
et al., 2002; Tsubokawa et al., 2006; Anagli et al., 2008; Luo et al.,
2010). The epoxysuccinyl peptides CA-074 (N-(L-3-trans-carbox-
yoxirane-2-cabonyl)-L-isoleucyl- L-proline) is known to be a speciﬁc
inhibitor of cathepsin B, while E-64c (N-(L-3-trans- carboxyoxirane-
2-carbonyl)-L-leucine-3-methylbutylamide) is known to inhibit
cathepsins B and L and calpain (Hashida et al., 1980). Accordingly,
the neuroprotective effect of E64-c is much stronger than CA-074;
approximately 67% of hippocampal CA1 neurons were saved from
delayed neuronal death by CA-074 on day 5 in monkeys undergoing
20 min brain ischemia (Yamashima et al., 1998), while approxi-
mately 84% of CA1 neurons were saved by E64-c in the same
experimental paradigm (Tsuchiya et al., 1999). These studies on the
non-AD models indicate that the neuroprotective effects of E64-c
occur by the inhibitions of both calpain and cathepsins, rather than
the Ab lowering effect. Similarly, preictal administration of
pyridoxal (Vitamin B6) showed some neuroprotective effects against
transient ischemia in both hippocampal and retina neurons, because
the active aldehyde at position 4 of the pyridine ring has an afﬁnity
for the active site -SH of cysteine residues of cathepsins B and L
(Yamashima et al., 2001; Wang et al., 2002). Accordingly,
supplementary intake of Vitamin B6might, more or less, contributes
to preventing Alzheimer neuronal death by inhibiting cathepsin B.
Since currently-available drugs such as acetylcholinesterase
inhibitors and N-methyl-D-aspartate receptor antagonists are only
for the partial symptomatic relief trying to slow deterioration ofPlease cite this article in press as: Yamashima, T., Reconsider Alzheim
review. Prog. Neurobiol. (2013), http://dx.doi.org/10.1016/j.pneurobthe patients, there is a signiﬁcant need of new concepts for
developing a novel strategy that can modify the underlying
causative factors of the disease. The most promising preventive
interventions in AD are preictal inhibitions of oxidative stresses,
HNE production, and calpain overactivation, eventually for the
blockade of ‘calpain-mediated cleavage of carbonylated Hsp70.10.
Hsp70.1 has a pivotal role in regulating the life and death of
neurons. Since ‘calpain-mediated cleavage of cabonylated Hsp70.10
is central in the pathogenesis of Alzhemeir neuronal death, agents
protecting Hsp70.1 from HNE carbonylation and calpain cleavage
can serve as critical targets for the therapeutic drug development.
However, given the known role of calpains in key cell processes
such as mitosis, cell cycle regulation, differentiation, cell migra-
tion, adhesion, and signal transduction (Suzuki et al., 2004),
nonspeciﬁc calpain inhibition is a potentially unacceptable
therapeutic strategy. In this sence, NSAID, often utilized for the
treatment of rheumatoid arthritis, may be useful for the calpain
inhibition with little adverse effect (Raveendran et al., 2008; Silver
et al., 2010) (Fig. 10).
Furthermore, for the protection of Hsp70.1 from the oxidative
stresses, it seems prudent to develop drugs and other treatments
that target HNE itself. Molecules that quench/detoxify HNE include
glutathione-S-transferases, histidine analog (histidyl hydrazide),
N-acetylcysteine, taurine, and carnosine derivatives as well as
various anti-lipid peroxidation agents (Mattson, 2009). Energy-
dense, high-fat ‘fast-food’ increases the plasma HNE signiﬁcantly
within minutes to hours, whereas dietary energy restriction
reduces HNE production and enhances HNE detoxiﬁcation
(Johnson et al., 2007; Devaraj et al., 2008). Accordingly, changes
of the dietary and lifestyle factors are essentially indispensable,
and should be practiced consistently. One should avoid excessive
intake of linoleic acids especially involved in soybean and corn oils,
because these vegetable oils may generate abundant HNE when
cooked at frying temperature (Seppanen and Csallany, 2006; Han
and Csallany, 2008). Another promising therapeutic approach for
AD is restoring functional Hsp70.1 proteins, for example, by the
replacement therapy or transferring Hsp genes into the degen-
erating neurons. Of course, improvement of ASM function by gene
therapy for preventing lysosomal lipidosis and the resultant
rupture, if possible, becomes one of the therapeutic options.
The membrane lipid peroxidation product HNE is recently
recognized as a particularly important mediator of cell degenera-
tion and dysfunction in a range of disorders including cardiovas-
cular disease, stroke, arthritis, diabetes, atherosclerosis, and
asthma as well as AD (Mattson, 2009). However, the concept of
HNE-induced lysosomal rupture was ﬁrst described in this review
as a cause of the Alzheimer neuronal death. Advances in the
research of programmed neuronal necrosis using ischemic monkey
experimental paradigms (Yamashima et al., 1996, 1998, 2003;
Yamashima, 2000, 2004, 2012; Oikawa et al., 2009, Yamashima and
Oikawa, 2009; Sahara and Yamashima, 2010; Zhu et al., 2012)
promise rapid progress of therapeutic strategy for not only AD but
also other neurodegenerative diseases in the very near future.
7. Concluding remarks
A continuum of abnormalities of the autophagic-lysosomal
system can be identiﬁed in neurons of the AD brain. Lysosomes of
the degenerating neurons prior to cell death often show
accumulations of granulo-vacuolar degenerations on light micros-
copy while multilamellar phospholipidosis on electron microsco-
py. Although it is difﬁcult to pinpoint the triggering event, recent
data suggest that Alzheimer neuronal death may be triggered by
long-standing, silent brain ischemia due to aging. The resultant
activation of calpain over years as well as generation of HNE due to
the oxidative stresses should be crucial for the development ofer’s disease by the ‘calpain–cathepsin hypothesis’—A perspective
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HNE generation as well as apoE’s detoxifying capacity of HNE may
determine individual risk for AD. Ab will merely facilitate
vulnerability of primarily ischemic neuronal cells by exaggerating
calpain activation and HNE-mediated carbonylation of Hsp70.1.
Calpain-mediated cleavage of the carbonylated Hsp70.1, via
inactivation of BMP, leads initially to lysosomal sphingolipidosis,
and ultimately to deprivation of ceramide at the lysosomal
membrane. This causes destabilization and/or rupture of the
lysosomal membranes with the concomitant release of cathepsin
enzymes into the cytoplasm. Furthermore, Hsp70.1 dysfunction
causes aggregation of phosphorylated tau and disturbance of the
axonal transport. These would altogether impair the cytoprotec-
tion machinery being afforded by the elimination of potentially
toxic oxidized proteins and membrane lipids. Accordingly, it is
likely that the common molecular cascade exists between ischemic
and Alzheimer neuronal death, and the latter occurs not by
apoptosis but by programmed necrosis. A new insight into the
Alzheimer neuronal death, based on the ‘calpain–cathepsin
hypothesis’ being formulated for ischemic neuronal death, would
contribute not only to elucidating the molecular cascade of
Alzheimer neuronal death (Fig. 10) but also to developing an
effective AD therapeutic strategy.
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